BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>editorial.bmjopen@bmj.com</u>

BMJ Open

Investigating Canadian parents' HPV vaccine knowledge, attitudes, and behaviour: A study protocol for a longitudinal national online survey

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-017814
Article Type:	Protocol
Date Submitted by the Author:	18-May-2017
Complete List of Authors:	Shapiro, Gilla; McGill University, Psychology Perez, Samara; McGill University, Naz, Anila Tatar, Ovidiu Guichon, Juliet Amsel, Rhonda Zimet, Gregory; Indiana University, Pediatrics Rosberger, Zeev
Primary Subject Heading :	Infectious diseases
Secondary Subject Heading:	Health services research, Oncology, Paediatrics, Public health, Sexual health
Keywords:	Human papillomavirus, Canada, adolescent health, sexually transmitted infections, cancer prevention, vaccination

SCHOLARONE[™] Manuscripts

BMJ Open

Investigating Canadian parents' HPV vaccine knowledge, attitudes, and behaviour: A study protocol for a longitudinal national online survey

Gilla K. Shapiro^{1,2,*}, MA (*Cantab*), MPP/MPA, PhD(c); Samara Perez, PhD^{1,2}; Anila Naz², MD, MPH, MSc; Ovidiu Tatar², MD, MSc; Juliet R. Guichon³, BCL, MA (*Oxon*), SJD; Rhonda Amsel¹, MD, MSc, FCFP, DrPH; Gregory D. Zimet⁴, PhD, HSPP; Zeev Rosberger^{1,2,5,6}, PhD

***Corresponding author:** Gilla K. Shapiro, MA (*Cantab*), MPP/MPA, PhD(c), Department of Psychology, McGill University, 1205 Dr. Penfield Avenue, Montreal, Quebec, H3A 1B1; Tel: (514) 340-8222, Ext. 3978; E-mail: <u>gilla.shapiro@mail.mcgill.ca</u>

¹Department of Psychology, McGill University 1205 Dr. Penfield Avenue, Montreal, Quebec, H3A 1B1, Canada

²Lady Davis Institute for Medical Research, Jewish General Hospital 4333 Cote St-Catherine Road, Montreal, Quebec, H3T 1E4, Canada

³Department of Community Health Sciences, Faculty of Medicine, University of Calgary 3280 Hospital Drive, Calgary, Alberta, T2N 4N1, Canada

⁴Section of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, 410 West 10th Street, Suite 1001, Indianapolis, Indiana, 46202, USA

⁵Louise Granofsky Psychosocial Oncology Program, Segal Cancer Center, Jewish General Hospital, 4333 Cote St-Catherine Road, Montreal, Quebec, H3T 1E4, Canada

⁶Departments of Psychiatry and Oncology, McGill University 1205 Dr. Penfield Avenue, Montreal, Quebec, H3A 1B1, Canada

Word Count: 4,101

ABSTRACT

Introduction: Human papillomavirus (HPV), a sexually transmitted infection, can cause anogenital warts and a number of cancers. To prevent morbidity and mortality, three vaccines have been licensed and are recommended by Canada's National Advisory Committee on Immunization (for females since 2007 and males since 2012). Nevertheless, HPV vaccine coverage in Canada remains suboptimal in many regions. This study will be the first to concurrently examine the correlates of HPV vaccine decision-making in parents of school-aged girls and boys, and evaluate changes in parental knowledge, attitudes and behaviours over time.

Methods and analysis: Using a national, online survey utilizing theoretically driven constructs and validated measures, this study will identify HPV vaccine coverage rates and correlates of vaccine decision-making in Canada at two time points (August-September, 2016; and June-July, 2017). 4606 participants will be recruited to participate in an online survey through a market research and polling firm using email inventions. Data cleaning methods will identify inattentive or unmotivated participants.

Ethics and dissemination: The study received research ethics board approval from the Research Review Office, Integrated Health and Social Services University Network for West-Central Montreal (CODIM-FLP-16-219). The study will adopt a multi-modal approach to disseminate the study's findings to researchers, clinicians, cancer and immunization organizations, and the public in Canada and internationally.

Discussion: This study will elucidate the factors that influence Canadian parents to vaccinate their sons or daughters. The results will provide public health officials with critical information about HPV vaccination programs, improve the fields' understanding of influencers of decision-making, improve and enhance the delivery of current publicly funded HPV vaccination program, facilitate HPV vaccine uptake, and in turn decrease Canada's cancer burden and the associated human and economic cost.

KEYWORDS

Attitudes, behaviour, Canada, cancer prevention, decision-making, human papillomavirus, knowledge, sexually transmitted infections, parents, vaccination.

to beet tellien only

ARTICLE SUMMARY

Article Focus:

• To explore the psychosocial factors that influence parents to vaccinate their sons or daughters with the HPV vaccine, and evaluate changes in parental vaccine knowledge, attitudes and behaviours over time.

Key Messages:

- The oncogenic protection offered by the human papillomavirus (HPV) vaccines has been recognized. However, HPV vaccination programs in Canada are not reaching their target rates of immunization and vary considerably by region. Determining HPV vaccine coverage and understanding why parents are choosing not to vaccinate their children are research priorities of the National Advisory Committee on Immunization and Canadian Immunization Committee.
- This project aims to examine the psychosocial and behavioural factors associated with parents' decisions to consent to their child receiving the HPV vaccine. Specifically, this research will describe HPV vaccine coverage in boys and girls; assess the correlates of HPV vaccination in parents of boys and girls; identify parents' stage of decision-making by gender and region; and determine the impact of publicly funded HPV vaccine program initiation for boys on parents' HPV vaccine attitudes and knowledge.
- The findings of this research will have implications for the development of tailored and targeted interventions, program delivery including closing disparities in vaccination, and improving the field's theoretical understanding of vaccine decision making.

Strengths and limitations of this study:

- Strengths of the study include a large sample size (n=4606), a nationally representative sample, use of psychometrically validated scales, the use of theoretical frameworks, a mixed methods approach, a wider range of constructs than in previous studies, and sophisticated data cleaning techniques to exclude inattentive or unmotivated responders.
- Limitations of this study include the reliance on self-reported data.

BMJ Open

INTRODUCTION

Human papillomavirus (HPV) is the most common sexually transmitted infection.¹⁻⁴ While most HPV infections are asymptomatic and do not progress to disease,⁵⁻⁷ some infections can cause substantial morbidity and mortality.⁸⁻¹¹ It is estimated that 5.2% of all worldwide cancers are attributable to HPV.¹¹⁻¹³ HPV-associated cancers include cervical, oropharyngeal, anal, vaginal, vulvar, and penile.^{9 11} Combined, HPV is responsible for over 4,000 new cancer cases annually in Canada.⁹ Certain strains of HPV (e.g. HPV 6/11) also cause anogenital warts.¹⁴ HPV-associated disease can impact quality of life and accrue substantial costs to the health care system.^{9 10 15}

Three prophylactic vaccines that prevent against the oncogenic strains of HPV have been developed and recommended: the bivalent Cervarix[®], quadrivalent Gardasil[®], and nonavalent Gardasil[®]9.¹⁶ These vaccines are safe and effective.¹⁷⁻²³ Canada's National Advisory Committee on Immunization (NACI) has recommended the HPV vaccines for females (since 2007) and males (since 2012) ages 9 to 26.^{16 2} From 2007 to 2010, all Canadian provinces and territories implemented publicly funded, school-based vaccination programs for females, albeit at different ages (i.e. 9 to 13 years of age) and with different dosing schedules (i.e. two or three doses).^{24 25} Vaccinating children at this age provides the highest level of immunogenicity and protects individuals before they are sexually active and thereby at risk of infection.^{9 20} This approach is similar to the majority of countries that provide publicly funded HPV vaccination programs to females.²⁶

To date, only a handful of countries have extended their publicly funded, school-based HPV vaccination programs to males.^{27 25 28} Canada has been an international leader in providing gender-neutral HPV vaccination;²⁵ by September 2017, 10 of Canada's 13 regions will have commenced school-based HPV vaccination programs that include boys (Figure 1).²⁹⁻³⁶ However, implementation of male HPV vaccination across Canada has been staggered, presenting a natural experiment to evaluate and compare the impact of the introduction of the HPV program on parents' attitudes, knowledge, and vaccine coverage.

Achieving high levels of vaccine coverage protects individuals and helps prevent transmission to unvaccinated partners, which maximizes population-level effectiveness (i.e. through herd protection).³⁷ HPV vaccination programs in Canada are not reaching their target

rates of immunization.^{38 39} HPV vaccine uptake rates in Canada vary considerably by region; in a national survey of parents of 12-14 year old girls, Gilbert et al. reported vaccination rates between 52.6% and 89.7% (2013 data).⁴⁰ On average, HPV vaccine uptake across Canada was 72.3%.⁴⁰ Preliminary evidence for boys in P.E.I.'s school-based vaccination program indicates 85.4% vaccine uptake (2013/2014 data).²⁹ However, a national survey of Canadian parents found uptake rates for boys in the context of (only one then two) publicly funded school-based programs, was extremely low (<3% nationwide; 2013 data).⁴¹ The lack of a national immunization registry makes it difficult to compare HPV vaccine coverage rates, and no national survey has yet examined HPV vaccine coverage in boys and girls simultaneously.

Given that parental consent is required for school-based immunisation programs for children in Canada, the NACI and Canadian Immunization Committee (CIC)^{9 24} have made it a research priority to understand why parents delay or refuse to vaccinate their children. Accordingly, this study seeks to understand the sociodemographic, psychosocial, and behavioural correlates of HPV vaccine coverage. Over the last decade, a number of studies have identified factors associated with HPV vaccination decision making including demographics, knowledge, attitudes, social norms, logistics (e.g. time, effort), and cost.⁴²⁻⁵³ The evidence has indicated some common themes (e.g. the importance of physician recommendation, perceived benefit, perceived safety, cost), and some contradictory evidence (e.g. knowledge has been found to correlate both negatively and positively with vaccine acceptance).^{48 49 54} The degree to which each of these factors contributes (i.e. the effect size) and possible policy variations between jurisdictions remains largely unclear. In addition, despite several systematic reviews,^{48 49 51 53 55} not all potentially relevant factors (e.g. the effect of vaccine conspiracy beliefs) have been identified or comprehensively investigated in large population-based studies, especially in the Canadian context.⁵⁶ Furthermore, the majority of studies addressing parental HPV vaccine decision-making have been primarily focused on parents of females,^{40 57} with fewer studies evaluating and making comparisons with parental HPV vaccine decision-making for boys.⁵⁸⁻⁶⁰

The present study aims to address these research gaps. Using a national, online survey utilizing theoretically driven constructs and validated questionnaires, this study identifies HPV vaccine coverage and correlates of decision-making in Canada. It will be the first to study concurrently the correlates of decision-making in parents of eligible school-aged boys and girls. This study will administer a survey at two time points (August-September, 2016; and June-July,

BMJ Open

2017) to capture important factors related to HPV vaccine hesitancy, acceptance and variation over time. Accordingly, this study will elucidate psychosocial factors that influence parents to vaccinate their sons or daughters contemporaneously and evaluate changes in parental knowledge, attitudes and behaviours over time.

Study Objectives and Hypotheses

The main objectives of this study are:

1. To describe HPV vaccine coverage in Canadian boys and girls

In the absence of a national immunization registry,⁶¹ current information on HPV vaccine coverage is unclear and continually evolving. We aim to determine HPV vaccine coverage in boys and girls nationally and across Canadian jurisdiction, and how rates change over time.

2. To assess the correlates of HPV vaccination in parents of boys and girls

In order to improve programs, it is important to understand the factors associated with HPV vaccine uptake. To date, Canadian studies have assessed the correlates of HPV vaccine uptake in parents of girls and parents of boys separately.^{52 58} Because the HPV vaccine uptake in both these groups, using constructs from the Health Belief Model (HBM), a commonly used theoretical model that includes core beliefs that are hypothesized to predict the adoption of new health behaviours.⁶² The HBM has been used to examine various health-related behaviours, including cancer prevention and vaccination.^{63 64} As applied to HPV vaccination, elements of the HBM include perceived benefits of, and barriers to, HPV vaccination; perceived severity of, and susceptibility to, HPV infection and disease; and external influences prompting HPV vaccine uptake (i.e. cues to action). This study will use HBM constructs and other important predictors to evaluate, compare, and contrast. We hypothesize that higher HPV vaccine uptake will be significantly related to greater HPV knowledge, HBM constructs (particularly lower 'barriers' and more 'cues to action'), non-HBM attitudinal constructs (e.g. lower vaccine conspiracy

beliefs), and health care provider (HCP) recommendation. In parents of boys, a publicly funded program (that reduces barriers of cost and access) and HCP recommendation are hypothesized to be particularly important.

3. To identify Canadian parents' stage of decision-making by gender and province

Few studies have examined the stages of parents' vaccine decision. Assessing differences in parents' HPV vaccine decision-making stage is important for identifying how best to intervene for parents at different stages.^{58 65} Using the Precaution Adoption Process Model (PAPM), a stage-based theoretical model, we will classify parents according to their unique stage of HPV vaccine decision-making and examine the associated attitudes with that stage.⁶⁵⁻⁶⁷ The PAPM, as applied to HPV vaccination, identifies individuals along six stages of decision-making: 1) unaware of the vaccine; 2) unengaged in the decision to vaccinate their child; 3) undecided about whether to vaccinate their child; 4) *decided not to act* (i.e. decided not to vaccinate their child); 5) decided to act (i.e. decided to vaccinate their child); and 6) acted (i.e. vaccinated their child) (see Supplementary File). We will compare the stage of decision-making of parents of girls with boys, as well as the stages of parents in those regions that have publicly funded programs for boys (P.E.I., Alberta, Nova Scotia, Ontario, Quebec, Manitoba) with those that do not (i.e. British Columbia, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nunavut, Saskatchewan, Yukon). We hypothesize that parents of boys will be in earlier PAPM stages compared to parents of girls, and that parents of boys in regions without an HPV vaccine program will be in earlier stages compared to parents of boys in regions with a program.

4. To determine the impact of publicly funded HPV vaccine program initiation for boys

HPV vaccination programs for boys were implemented in Quebec, Ontario and Manitoba in the Fall of 2016, which is after Time 1 survey administration (August-September 2016), but before launching the Time 2 survey (June-July 2017). This natural experiment allows us to evaluate the impact of introducing a public school-based HPV vaccination program on parents' HPV vaccine knowledge, attitudes, and HPV vaccine coverage. Accordingly, we will evaluate whether these factors change from Time 1 to Time 2. We hypothesize that compared to programs

BMJ Open

with no change to their public vaccination program, at Time 2 (post-intervention) parents of boys in Manitoba, Ontario and Quebec will have increased HPV vaccine knowledge, more positive HPV vaccine attitudes, be more likely to have received a HCP's recommendation, and be more likely to have received the HPV vaccine. British Columbia, Saskatchewan, New Brunswick, and Newfoundland and Labrador have announced that they would fund HPV vaccine for boys to begin in September 2017 (Figure 1); this research will therefore have value in predicting how parental attitudes regarding vaccinating their sons might change in those jurisdictions.

METHODS AND ANALYSIS

Design

This study uses a longitudinal cross-sectional design to collect self-reported data through an online questionnaire from a large national sample of Canadian parents. Surveys are administered at two time points: Time 1 during August-September (2016) and Time 2 during June-July (2017).

Sample

This study targets parents and guardians (hereafter referred to as "parents") of 9 to 16year-old boys and girls across Canada. This population is targeted because, on the younger side (i.e. age 9), it includes the youngest children included in NACI's recommendation and, on the older side (i.e. age 16), it includes children who, generally speaking, require parental consent in Canada.⁶⁸ Parents will be recruited by Canada's largest market research and polling firm, Leger-*The Research Intelligence Group*. Leger maintains a national panel of 400,000 Canadians who have Internet access, reside in Canada, and are fluent in English or French. This study targeted parents who have a child between 9-16 years of age living in their household. Participants completing the questionnaire at Time 1 will be contacted again at Time 2.

Leger's panels include individuals of all profiles with regard to gender, age, education level, household composition and income for all regions, making it feasible to effectively target

specific participants.⁶⁷ The panel is constructed to be nationally, as well as regionally, representative. Leger uses proprietary software informed by Canada's census data in order to generate a representative sample of the population. Leger's software follows an interactive algorithm to invite participants according to specified eligibility criteria. In this study, Leger's software enables extraction of all active and available panellists who meet the screening criteria, random sorting of the selected sample pool, examination of the number of panellists who satisfy each target group (i.e. parents of a 9-16 year old boys or parents of a 9-16 year old girls), and recalculation and balancing of the sample across the target groups. To recruit participants, Leger sends an email invitation and survey link to selected panellists. Leger sends a maximum of three reminder emails to its selected panellists to complete the survey until the required numbers of participants are recruited.

This study's sample size calculation takes into account previous research indicating that approximately 15% of respondents are inattentive or unmotivated responders who would be excluded using rigorous data cleaning methods.^{66 69} To evaluate different stages of decision making (objective 3), we are guided by previous research that found few individuals in particular stages (especially in less populated regions).⁶⁶ An attrition rate (of approximately 40-50%) from the first wave of data collection (Time 1, August-September 2016) to the second wave (Time 2, June-July 2017) is also expected.⁶⁶ Therefore, in order to attain a sufficient number of respondents to enable analyses of HPV vaccine decision-making by stage and region, this study recruits approximately 4,600 parents of school-aged children (ages 9-16) at Time 1, equally divided between parents of boys and parents of girls.

Measures

We use an online questionnaire that incorporates intelligent programming, such that the child's first name is included in the survey questions and parents receive questions that are personalized for them. Questionnaire items include previously validated scales.^{56 70-73} Participants will be asked to identify themselves as a parent or guardian, report the number of children they have, and their children's ages and genders. Parents with more than one child who meets the inclusion criteria will be asked to answer the questionnaire for the child who has had the most recent birthday, a randomization technique previously employed.⁶⁶ The questionnaire

assesses socio-demographics; HPV and HPV vaccine knowledge (using validated scales);⁷¹ PAPM stage; HPV vaccine willingness; HPV vaccine coverage; HCP recommendation (including the strength of the recommendation); HPV attitudes (using validated scales);^{73 74} motivation towards vaccination; vaccine hesitancy (using a developed scale);⁵⁶ and vaccine conspiracy beliefs (using a validated scale).⁷⁰ Items within validated questionnaires are administered in a random order to ameliorate any order effect and invariant responding.⁷⁵ Five open-ended qualitative questions will provide nuance in capturing details of parents' subjective perspectives on decision-making. A detailed description of the questionnaire's items can be found in the Supplementary File.

To take into account language and literacy level, the questionnaire was adjusted to a grade eight reading level. To ensure the questionnaire could be answered in either of Canada's national languages, the English questionnaire was translated into French using Asiatis, an international translation service company. Bilingual team members verified the French translation and back-translation.

Data Collection and Management

Leger will facilitate data collection. Participants will be sent an email invitation to participate in a questionnaire and then assigned a unique access number. By accessing the questionnaire with this unique number, the respondent enters a secure account that ensures confidentiality. Moreover, if necessary, respondents may stop and resume the questionnaire where they left off so that they participate at a time that best suits them, allowing them to complete the questionnaire conscientiously.

Participants will be paid a modest cash amount in accordance with standard panel member compensation of Leger. Data collection at both time periods will be completed within four weeks. Missing data will not be an obstacle in this survey because participants will be required to answer all questions before moving from one page to the next. Once participants complete the questionnaire they will be debriefed, informed about HPV vaccination, and provided with informational resources. Leger will transfer the anonymized raw data file to our research team, which will be stored on a secure server at the Lady Davis Institute for Medical Research site of the Integrated Health and Social Services University Network for West-Central Montreal.

Data Cleaning Procedure

As recommended in the literature,^{69 75 76} data cleaning methods will be used to identify participants who might not have used appropriate care while completing the questionnaire (i.e. inattentive or unmotivated responders). Consistent with DeSimone et al. (2015) and Perez et al. (2016), we will use data cleaning methods that are direct (i.e. bogus items) and statistical (i.e. psychometric synonyms and psychometric antonyms).^{66 75}

Bogus items will be used to screen inattentive or unmotivated responders. Two bogus items on Likert scales were randomly inserted into the survey: "I have never met anyone younger than I am" and "I have been to every country in the world" (measured from '1-strongly disagree' to '7-strongly agree'). Incorrect answers (i.e. agreement) to both bogus items suggest inattentive or unmotivated responders. Incorrect responses are indicative of lack of attention. Respondents who answer at least one bogus item correctly will be retained.

Psychometric synonyms and antonyms data cleaning methods statistically examines response patterns.⁶⁶ Providing different responses to similar items suggests insufficient attention and accuracy in answering the questionnaire. Items measured on Likert scales will be selected and inter-item correlations will be calculated. Positively correlated pairs of items will constitute psychometric synonyms while negatively correlated pairs will constitute psychometric antonyms.⁷⁵ The number of pairs cannot be anticipated before beginning data analysis because it depends on the degree of correlation and the chosen cut-off value of the correlation coefficient.⁷⁵ We will use an inter-item Pearson correlation cut-off of 0.60 and -0.60 for selecting psychometric synonyms and psychometric antonyms pairs respectively, consistent with recommendations of Meade and Craig (2012).⁷⁶ Once the pairs have been identified, an index will be calculated for each respondent by correlating the responses to the first items of the pairs with the responses to the second items of the pairs.

Responders who meet both the bogus item and the psychometric synonyms/antonyms criteria will be considered attentive responders and retained.

Data Analysis Plan

BMJ Open

In line with the first research objective to provide an accurate description of HPV vaccine coverage, we will report HPV vaccination coverage as percentage of girls and boys in each region and age group whose parents report they have received one, two, or three doses of the HPV vaccine. To test for statistically significant differences in proportions, we will use Pearson's Chi square tests and two sample tests of proportions.

For the second objective, to assess the correlates of HPV vaccine uptake in Canada, HPV vaccine uptake (dependent variable) will be dichotomised into "vaccinated" (i.e. received at least one dose of the HPV vaccine) and "non-vaccinated". Logistic regressions will be used to estimate the odds of vaccine uptake based on the correlates of interest, including socio-demographics, attitudes (informed by the HBM), knowledge, and behaviours (e.g. discussion with HCP). Significant associations between the correlates and vaccine uptake will be tested using bivariate logistic regression analyses. Multivariate logistic regression modelling will then be performed with all correlates from the bivariate analysis entered simultaneously. The model will be tested for goodness of fit, discrimination capacity, and multicollinearity.

To identify Canadian parents' stage of decision-making by gender and region (objective 3), we will report parents' HPV vaccine decision-making in percentages based on the six stages of the PAPM. For assessing significant differences in PAPM stage based on gender (at Time 1) and availability of publicly funded HPV vaccination programs for boys (at both Time 1 and Time 2), Pearson chi-square test and two sample tests of proportions will be used.

Lastly, to determine the impact of publicly funded HPV vaccine program initiation for boys in some regions, we will examine changes in parents' of boys (HPV and HPV vaccine) knowledge and attitudes (e.g. on the Human papillomavirus Attitudes and Beliefs Scale, Vaccine Conspiracy Beliefs Scale, and Vaccine Hesitancy Scale) before and after the introduction of the funded program. Parents of boys in provinces that introduced the program will be compared to parents of boys in regions with no change to their program. Significant differences from Time 1 to Time 2 will be tested using paired T-tests.

ETHICS AND DISSEMINATION

Study Ethics

The study received research ethics board approval from the Research Review Office, Integrated Health and Social Services University Network for West-Central Montreal (CODIM-FLP-16-219). This is a university-affiliated teaching health care network where the coordinating center (Lady Davis Institute for Medical Research) is based. Study participants consented to Leger's terms of use and privacy policy, which indicates that their data will be used anonymously for the research study.

Dissemination Plan

The study will adopt a multi-modal approach to disseminate the study's results to researchers, clinicians, cancer and vaccination organizations, and the public in Canada and internationally. Study findings will be published in peer-reviewed scientific journals (including open source). To assure wide availability of our results to the research community, journals will be selected that reach both research and health professional audiences.

Presentations will be made at national and international scientific meetings and symposia, such as the Canadian Immunization Conference, Canadian Association of Psychosocial Oncology, International Papillomavirus Society conference, and the International Psycho-Oncology Society. In addition, we will share the results with NACI, CIC, and provincial immunization advisory boards.

Given that the data is timely and could have immediate, direct implications for public education of Canadian parents, and more widespread influence on public health policy, we will prioritize analysis and dissemination of projects that have a potential for proximal public impact. We hope that sharing outcomes with non-profit organizations (e.g. the Canadian Cancer Society) will provide important platforms for innovative educational interventions based on this study's findings.

We will draft lay research summaries in media releases for dissemination to national media outlets and use such releases to help the public understand the importance of this research, bring the issues and challenges related to HPV vaccine acceptance to the public domain that will inform discussions about HPV vaccination.

DISCUSSION

Study Implications

By surveying a population-based representative sample of parents of eligible children, this study will provide current information about HPV vaccine coverage rates for both boys and girls nationally, and across Canadian jurisdictions (objective 1). Since HPV vaccine programs and policies are constantly evolving,²⁵ it is timely to evaluate comprehensively variations in program outcomes that target females and males, jurisdictions at a national and local level, and HPV vaccination by socio-demographic groups. For this reason, this study will be useful to policymakers in understanding where the HPV vaccination programs are meeting coverage targets, where disparities in vaccination exist, and which groups or jurisdictions may benefit from interventions designed to increase vaccination.

In order to improve the impact of publicly funded HPV vaccination programs, this study will examine the psychosocial and behavioural factors associated with parents' decisions to vaccinate their children and their decision-making stage (objectives 2 and 3). These theoretically driven investigations will enable policymakers to develop interventions to increase HPV vaccination that are evidence-based, tailored, and targeted towards parents' unique informational needs and their stage of decision-making, rather than providing all parents with the same messages.

Lastly, since Canada is one of the few countries that have implemented publicly-funded, national HPV vaccination programs, this research will make use of a natural experiment to evaluate the impact of the introduction of funded programs for boys on parents' vaccine knowledge, attitudes, and decision to vaccinate (objective 4). The results of this study will improve our understanding of the complex interplay of psychosocial and behavioural factors with policy decisions. By understanding this complexity, other countries can better anticipate that impact of policy changes.

The results generated by the study's four objectives will provide public health officials with critical information about HPV vaccination programs, improve the fields' understanding of

influencers of decision-making, improve and enhance the delivery of current publicly funded HPV vaccination program, facilitate HPV vaccine uptake, and in turn decrease Canada's cancer burden and the associated human and economic cost.

Methodological Strengths

The recruitment strategy of using a marketing company (Leger) that maintains a nationally representative panel for data collection enables the sampling of a large number of parents who answer the survey within a short time frame. The precise recruitment period allows for data collection to occur in a timely manner and the provision of a snapshot of responses before and after the implementation of the HPV vaccination program for boys in certain provinces.

In addition, we use an online survey methodology with intelligent programming, which increases the quality of collected data by personalizing and tailoring the survey for each participant. This study also avoids the problems associated with missing data. To avoid the limitation of inattentive or unmotivated responding that is often found in survey data, this study will utilize sophisticated data cleaning techniques to remove such responders.

Further, the measures used in this study include psychometrically validated scales (where possible), which increase the reliability and validity of our results. Our survey also assesses many and diverse constructs. By using theoretical frameworks (such as the HBM and PAPM), we will be able to better understand the vaccine acceptability process, which is important in nuanced targeting of interventions. Lastly, by including quantitative and qualitative (open-ended) questions, we will be able to conduct additional mixed-methods studies to examine indepth explanations of HPV vaccine decision making at different stage levels.

Foreseeable Limitations

One limitation is the reliance on parents' self-reports of vaccination status of their children. In order to minimize this limitation, parents are asked about their vaccination status before and after reading an informative statement (whereby parents are provided details about the HPV vaccine). The exact number of reported doses (two or three) could also be inaccurate.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

A possible way to confirm immunisation status is to request parents to check the immunisation record, contact the family doctor, or link to provincial immunization records. However, requesting participants to access records was not feasible in our study as such a request would have significantly increased the data collection time and costs.

to peer terier only

Acknowledgements: The authors appreciate the guidance and expertise of Dr. Eve Dubé, Dr. Vladimir Gilca, Prof. Gina Ogilvie, and Prof. Eduardo Franco.

Contributors: GS conceived and designed the study, developed the survey, and wrote the manuscript. AN and OT participated in designing the study, assisted in drafting the manuscript, and provided critical feedback on manuscript revisions. SP, JG, GZ, RA provided critical feedback on manuscript revisions. ZR conceived and designed the study, developed the survey, and provided critical feedback on manuscript revisions. All authors read and approved the final manuscript.

Funding: This work was supported by the Canadian Cancer Society Research Institute under the title: Understanding HPV Vaccine Hesitancy among Canadian Parents (Grant number: 704036). GS was supported by the Vanier Canada Graduate Scholarship and Queen Elizabeth II Diamond Jubilee Scholarship programs.

Competing Interests: ZR reports grants from the Canadian Cancer Society Research Institute during the conduct of the study, and personal fees from Merck outside the submitted work. GZ reports grants from Merck, and personal fees from Sanofi Pasteur, outside the submitted work. The remaining authors declare no conflict of interest.

Ethics approval: The study received research ethics board approval from the Research Review Office, Integrated Health and Social Services University Network for West-Central Montreal (CODIM-FLP-16-219).

Data sharing statement: Please contact the corresponding author if you are interested in using our survey or data.

BMJ Open

REFERENCES

- 1. Shearer BD. HPV Vaccination: Understanding the Impact on HPV Disease. *Purple Paper* 2011; 34. <u>http://www.nccid.ca/files/Purple_Paper_Note_mauve/PP_34_EN.pdf</u>.
- 2. National Advisory Committee on Immunization. Update on the recommended Human Papillomavirus vaccine immunization schedule 2015 [Available from: <u>http://publications.gc.ca/collections/collection_2015/aspc-phac/HP40-128-2014-eng.pdf</u> accessed May 08 2017.
- 3. Crosbie EJ, Einstein MH, Franceschi S, et al. Human papillomavirus and cervical cancer. *Lancet* 2013;382(9895):889-99. doi: 10.1016/S0140-6736(13)60022-7
- 4. Moore RA, Ogilvie G, Fornika D, et al. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination. *Cancer Causes Control* 2009;20(8):1387-96. doi: 10.1007/s10552-009-9365-4
- 5. Little KQ, Ogilvie G, Mirwaldt P. Human papillomavirus awareness, knowledge, and vaccination status in a diverse population of male postsecondary students in Greater Vancouver. *British Columbia Medical Journal* 2015;57(2)
- 6. Parkin DM, Bray F. The burden of HPV-related cancers. *Vaccine* 2006;24:S11-S25.
- 7. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. *Gynecol Oncol* 2007;107(2 Suppl 1):S2-5. doi: 10.1016/j.ygyno.2007.07.067
- 8. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens Part B: biological agents. *The Lancet Oncol* 2009;10(4):321-22.
- 9. National Advisory Committee on Immunization. Update On Human Papillomavirus Vaccines. *Canada Communicable Disease Report* 2012;38
- 10. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. *Vaccine* 2012;30 Suppl 5:F12-23. doi: 10.1016/j.vaccine.2012.07.055
- 11. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *Lancet Oncol* 2012;13(6):607-15. doi: 10.1016/S1470-2045(12)70137-7
- 12. Parkin DM. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer* 2006;118(12):3030-44. doi: 10.1002/ijc.21731
- 13. Oh JK, Weiderpass E. Infection and cancer: global distribution and burden of diseases. *Ann Glob Health* 2014;80(5):384-92. doi: 10.1016/j.aogh.2014.09.013
- 14. Ball SL, Winder DM, Vaughan K, et al. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. *J Med Virol* 2011;83(8):1345-50. doi: 10.1002/jmv.22111
- 15. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. *Sex Transm Infect* 2009;85(2):111-5. doi: 10.1136/sti.2008.030999
- 16. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Updated Recommendations on Human Papillomavirus (HPV) vaccines: 9-valent HPV vaccine and clarification of minimmum intervals between doses in the HPV immunization schedules Ontario, Canada2016 [Available from: http://www.healthycanadians.gc.ca/publications/healthy-living-vie-saine/humanpapillomavirus-9-valent-vaccine-update-recommendation-mises-a-jour-


<u>recommandations-papillome-humain-vaccin-nonavalent/alt/hpv-phv-eng.pdf</u> accessed February 14 2017.

- 17. Szarewski A, Poppe WA, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. *Int J Cancer* 2012;131(1):106-16. doi: 10.1002/ijc.26362
- 18. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. *Cancer Prev Res (Phila)* 2009;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031
- 19. Group FIIS, Dillner J, Kjaer SK, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. *BMJ* 2010;341:c3493. doi: 10.1136/bmj.c3493
- 20. Ferris D, Samakoses R, Block SL, et al. Long-term study of a quadrivalent human papillomavirus vaccine. *Pediatrics* 2014;134(3):e657-65. doi: 10.1542/peds.2013-4144
- 21. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *J Natl Cancer Inst* 2010;102(5):325-39. doi: 10.1093/jnci/djp534
- 22. Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. *Expert Opin Drug Saf* 2015;14(5):697-712. doi: 10.1517/14740338.2015.1013532
- 23. Ogilvie GS, Naus M, Money DM, et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. *Int J Cancer* 2015;137(8):1931-7. doi: 10.1002/ijc.29508
- 24. Canadian Immunization Committee. Recommendations for human papillomavirus immunization programs. *Canada Communicable Disease Report* 2014;40(8)
- 25. Shapiro GK, Guichon J, Prue G, et al. A Multiple Streams analysis of the decisions to fund gender-neutral HPV vaccination in Canada. *Prev Med* 2017;100:123-31. doi: 10.1016/j.ypmed.2017.04.016
- 26. Bonanni P, Bechini A, Donato R, et al. Human papilloma virus vaccination: impact and recommendations across the world. *Ther Adv Vaccines* 2015;3(1):3-12. doi: 10.1177/2051013614557476
- 27. Marsh K, Chapman R, Baggaley RF, et al. Mind the gaps: what's missing from current economic evaluations of universal HPV vaccination? *Vaccine* 2014;32(30):3732-9. doi: 10.1016/j.vaccine.2014.05.007
- 28. Patel C, Macartney K. Supporting the call for a gender-neutral human papillomavirus vaccination in Canada. *Cmaj* 2017;189(3):E118. doi: 10.1503/cmaj.732446
- 29. McClure CA, MacSwain MA, Morrison H, et al. Human papillomavirus vaccine uptake in boys and girls in a school-based vaccine delivery program in Prince Edward Island, Canada. *Vaccine* 2015;33(15):1786-90. doi: 10.1016/j.vaccine.2015.02.047
- 30. Public Health Agency of Canada. Canada's Provincial and Territorial Routine (and Catch-up) Vaccination Programs for Infants and Children. 2017 [Available from: <u>http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php</u> accessed May 08 2017.

Page 21 of 2	8	BMJ Open
1 2		
3 4 5 6	31.	Colbert Y. HPV vaccine for Nova Scotia boys called 'groundbreaking': CBC News; 2015 [Available from: <u>http://www.cbc.ca/news/canada/nova-scotia/hpv-vaccine-for-nova-scotia-boys-called-groundbreaking-1.3031169</u> accessed May 07 2017.
7 8 9	32.	Shapiro GK, Perez S, Rosberger Z. Including males in Canadian human papillomavirus vaccination programs: a policy analysis. <i>Cmaj</i> 2016;188(12):881-6. doi: 10.1503/cmaj.150451
10 11 12 13 14	33.	Ghoussoub M. B.C. extends free HPV vaccinations to Grade 6 boys - British Columbia2017 [updated Jan 06, 2017. Available from: <u>http://www.cbc.ca/news/canada/british-columbia/b-c-extends-free-hpv-vaccinations-to-</u> grade-6-boys-1.3925212.
15 16 17 18 19	34.	Cover JK, Nghi NQ, LaMontagne DS, et al. Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. <i>BMC Public Health</i> 2012;12:629. doi: 10.1186/1471-2458-12-629
20 21 22	35.	Fong K. Grade 6 boys to start receiving HPV vaccination in Saskatchewan 2017 [updated March 23, 2017. Available from: <u>http://globalnews.ca/news/3331430/grade-6-boys-to-start-receiving-hpv-vaccinations-in-sask/</u> accessed May 08 2017.
23 24 25 26	36.	Boone M. Boys too: HPV vaccination to be offered to all N.L. students in Grade 6 2017 [updated May 04, 2017. Available from: <u>http://www.cbc.ca/news/canada/newfoundland-labrador/hpv-vaccine-boys-newfoundland-1.4098941</u> accessed May 08 2017.
27 28 29	37.	Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. <i>Lancet Infect Dis</i> 2015;15(5):565-80. doi: 10.1016/S1473-3099(14)71073-4
30 31 32	38.	Ministère de la Santé et des Services Sociaux. Programme National de Santé Publique. 2008. <u>http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2008/08-216-01.pdf</u> .
33 34 35	39.	Bogaards JA, Wallinga J, Brakenhoff RH, et al. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. <i>BMJ</i> 2015;350:h2016. doi: 10.1136/bmj.h2016
36 37 38 39 40	40.	Gilbert NL, Gilmour H, Dube E, et al. Estimates and determinants of HPV non-vaccination and vaccine refusal in girls 12 to 14 y of age in Canada: Results from the Childhood National Immunization Coverage Survey, 2013. <i>Hum Vaccin Immunother</i> 2016;12(6):1484-90. doi: 10.1080/21645515.2016.1153207
41 42 43 44	41.	Perez S, Shapiro GK, Brown CA, et al. 'I didn't even know boys could get the vaccine': Parents' reasons for human papillomavirus (HPV) vaccination decision making for their sons. <i>Psychooncology</i> 2015;24(10):1316-23. doi: 10.1002/pon.3894
45 46	42.	Ogilvie GS, Remple VP, Marra F, et al. Parental intention to have daughters receive the human papillomavirus vaccine. <i>Cmaj</i> 2007;177(12):1506-12. doi: 10.1503/cmaj.071022
47 48 49 50	43.	Allen JD, Coronado GD, Williams RS, et al. A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability. <i>Vaccine</i> 2010;28(24):4027-37. doi: 10.1016/j.vaccine.2010.03.063
51 52	44.	Krawczyk AL, Perez S, Lau E, et al. Human papillomavirus vaccination intentions and uptake in college women. <i>Health Psychol</i> 2012;31(5):685-93. doi: 10.1037/a0027012
53 54 55 56 57 58	45.	Ogilvie GS, Remple VP, Marra F, et al. Intention of parents to have male children vaccinated with the human papillomavirus vaccine. <i>Sex Transm Infect</i> 2008;84(4):318-23. doi: 10.1136/sti.2007.029389
59 60		21

- 46. Lee A, Ho M, Cheung CK, et al. Factors influencing adolescent girls' decision in initiation for human papillomavirus vaccination: a cross-sectional study in Hong Kong. *BMC Public Health* 2014;14:925. doi: 10.1186/1471-2458-14-925
 - 47. Zimet GD, Rosberger Z, Fisher WA, et al. Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation. *Prev Med* 2013;57(5):414-8. doi: 10.1016/j.ypmed.2013.05.013
 - 48. Hendry M, Lewis R, Clements A, et al. "HPV? Never heard of it!": a systematic review of girls' and parents' information needs, views and preferences about human papillomavirus vaccination. *Vaccine* 2013;31(45):5152-67. doi: 10.1016/j.vaccine.2013.08.091
 - 49. Holman DM, Benard V, Roland KB, et al. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. *JAMA Pediatr* 2014;168(1):76-82. doi: 10.1001/jamapediatrics.2013.2752
- 50. Patel PR, Berenson AB. Sources of HPV vaccine hesitancy in parents. *Hum Vaccin Immunother* 2013;9(12):2649-53. doi: 10.4161/hv.26224
- 51. Walhart T. Parents, adolescents, children and the human papillomavirus vaccine: a review. *Int Nurs Rev* 2012;59(3):305-11. doi: 10.1111/j.1466-7657.2012.00991.x
- 52. Krawczyk A, Knauper B, Gilca V, et al. Parents' decision-making about the human papillomavirus vaccine for their daughters: I. Quantitative results. *Hum Vaccin Immunother* 2015;11(2):322-9. doi: 10.1080/21645515.2014.1004030
- 53. Trim K, Nagji N, Elit L, et al. Parental Knowledge, Attitudes, and Behaviours towards Human Papillomavirus Vaccination for Their Children: A Systematic Review from 2001 to 2011. *Obstet Gynecol Int* 2012;2012:921236. doi: 10.1155/2012/921236
- 54. Gowda C, Dempsey AF. The rise (and fall?) of parental vaccine hesitancy. *Hum Vaccin Immunother* 2013;9(8):1755-62. doi: 10.4161/hv.25085
- 55. Garcini LM, Galvan T, Barnack-Tavlaris JL. The study of human papillomavirus (HPV) vaccine uptake from a parental perspective: a systematic review of observational studies in the United States. *Vaccine* 2012;30(31):4588-95. doi: 10.1016/j.vaccine.2012.04.096
- 56. Larson HJ, Jarrett C, Eckersberger E, et al. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. *Vaccine* 2014;32(19):2150-9. doi: 10.1016/j.vaccine.2014.01.081
- 57. Forster AS, Rockliffe L, Chorley AJ, et al. A qualitative systematic review of factors influencing parents' vaccination decision-making in the United Kingdom. *SSM Popul Health* 2016;2:603-12. doi: 10.1016/j.ssmph.2016.07.005
- 58. Perez S, Tatar O, Gilca V, et al. Untangling the psychosocial predictors of HPV vaccination decision-making stages among parents of boys. *Vaccine* 2017;Forthcoming
- 59. Lindley MC, Jeyarajah J, Yankey D, et al. Comparing human papillomavirus vaccine knowledge and intentions among parents of boys and girls. *Hum Vaccin Immunother* 2016;12(6):1519-27. doi: 10.1080/21645515.2016.1157673
- 60. Radisic G, Chapman J, Flight I, et al. Factors associated with parents' attitudes to the HPV vaccination of their adolescent sons : A systematic review. *Prev Med* 2017;95:26-37. doi: 10.1016/j.ypmed.2016.11.019
- 61. Government of Canada. Immunization coverage and registries 2016 [Available from: <u>https://www.canada.ca/en/public-health/services/immunization-coverage-</u> registries.html#a3 accessed February 07 2017.

Page 23 of 28	BMJ Open			
1 2				
3 62. 5 6	Champion VL, Skinner CS. The Health Belief Model. In: Glanz K, Rimer BK, Viswanath KE, eds. Health behavior and health education: theory, research, and practice. 4th ed: John Wiley & Sons 2008:45-65.			
7 63. 8	Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. <i>Prev Med</i> 2007;45(2-3):107-14. doi: 10.1016/j.ypmed.2007.05.013			
9 64. 10 11	Cunningham MS, Davison C, Aronson KJ. HPV vaccine acceptability in Africa: a systematic review. <i>Prev Med</i> 2014;69:274-9. doi: 10.1016/j.ypmed.2014.08.035			
12 65. 13	Prue G, Santin O. HPV vaccine acceptance in male adolescents. <i>Psychooncology</i> 2015;24(10):1327-29. doi: 10.1002/pon.3961			
14 66. 15 16 17 18	Perez S, Tatar O, Shapiro GK, et al. Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study. <i>BMC Public Health</i> 2016;16(1):1223. doi: 10.1186/s12889-016-3828-9			
19 67.	Weinstein ND. The precaution adoption process. <i>Health Psychol</i> 1988;7(4):355-86.			
20 68. 21 22	Court of Appeal of Alberta. J.S.C. v. Wren, 1986 ABCA 249 (CanLII) 31-12-1986 [March 21, 2017]. Available from: http://www.canlii.org/en/ab/abca/doc/1986/1986abca249/1986abca249.html.			
23 24 25	Osborne JW. Best practices in data cleaning: A complete guide to everything you need to do before and after collecting your data: Sage Publications 2012.			
26 70. 27	Shapiro GK, Holding A, Perez S, et al. Validation of the vaccine conspiracy beliefs scale. <i>Papillomavirus Research</i> 2016;2:167-72. doi: 10.1016/j.pvr.2016.09.001			
28 71. 29 30 31	Perez S, Tatar O, Ostini R, et al. Extending and validating a human papillomavirus (HPV) knowledge measure in a national sample of Canadian parents of boys. <i>Prev Med</i> 2016;91:43-49. doi: 10.1016/j.ypmed.2016.07.017			
32 72. 33 34	Waller J, Ostini R, Marlow LA, et al. Validation of a measure of knowledge about human papillomavirus (HPV) using item response theory and classical test theory. <i>Prev Med</i> 2013;56(1):35-40.			
35 73. 36 37	McRee AL, Brewer NT, Reiter PL, et al. The Carolina HPV immunization attitudes and beliefs scale (CHIAS): scale development and associations with intentions to vaccinate. <i>Sex Transm Dis</i> 2010;37(4):234-9. doi: 10.1097/OLQ.0b013e3181c37e15			
38 39 74. 40 41	Perez S, Shapiro GK, Tatar O, et al. Development and Validation of the Human Papillomavirus Attitudes and Beliefs Scale in a National Canadian Sample. <i>Sex Transm Dis</i> 2016;43(10):626-32. doi: 10.1097/OLQ.00000000000000506			
42 75. 43 44	DeSimone JA, Harms PD, DeSimone AJ. Best practice recommendations for data screening. <i>Journal of Organizational Behavior</i> 2015;36(2):171-81.			
45 76. 46	Meade AW, Craig SB. Identifying careless responses in survey data. <i>Psychol Methods</i> 2012;17(3):437-55. doi: 10.1037/a0028085			
47 77. 48 49 70	Larson HJ, Jarrett C, Schulz WS, et al. Measuring vaccine hesitancy: The development of a survey tool. <i>Vaccine</i> 2015;33(34):4165-75. doi: 10.1016/j.vaccine.2015.04.037			
50 /8. 51 52 53 54 55 56 57	LaClair BJ, Smith S, Woodward J. Attitudes and concerns of Kansas parents related to childhood immunization. <i>Immunize Kansas Kids</i> 2014			
58 59 60	23			



Variables	Number of items	Sample items	Response choices	Instructions
Eligibility	5	Do you personally have a child between 9-16 years of age living in your household? ^a	Yes; No	
Socio-Demographics	18	In which province do you currently live? Which of the following ethnicities best describes you?	Categories derived from those commonly used by Statistics Canada. Prefer not to answer was an option for some items.	Select only one.
Precaution Adoption Process Model	1	Which of the following best described your thoughts about the human papillomavirus (HPV) vaccine for [CHILD]? ^c	Stage 1: I am <i>unaware</i> that the HPV vaccine could be given to [CHILD name]; Stage 2: I am aware that the HPV vaccine could be given to [CHILD name], but I have <i>never</i> <i>thought about</i> vaccinating [CHILD name] against HPV; Stage 3: I am <i>undecided</i> about vaccinating [CHILD name] against HPV; Stage 4: I have decided I DO <i>NOT</i> want to vaccinate [CHILD name] against HPV; Stage 5: I have decided I <i>DO</i> want to vaccinate [CHILD name] against HPV; Stage 6: [CHILD name] has <i>already received</i> the HPV vaccine. ^c	Select only one.
HPV & HPV Vaccine Perceived Knowledge	2	Before today, how much would you say you knew about the human papillomavirus (HPV)?	Nothing – A lot (5-point Likert scale)	Please answer the following questions to best of your ability.
HPV Knowledge ^{71 72}	23 ^b	HPV always has visible signs or symptoms (F) HPV can be passed on during sexual intercourse (T)	True; False; Don't know	Please answer the following questions ab human papillomavirus (HPV) to the best of yo ability.
HPV Vaccine Knowledge ^{71 72}	13 ^b	The HPV vaccine offers protection against most cervical cancers (T) Girls who have had the HPV vaccine do not need a Pap test when they are older (F)	True; False; Don't know	Please answer the following questions ab the human papillomavi (HPV) vaccine to the b of your ability.
Information Sources	2	Where have you heard about the HPV vaccine?	Categories include: Not applicable, I	Check all answers that

1
2 3 4 5 6 7 8
4 5
6 7
9
10 11
12 13
10 11 12 13 14 15
16 17
18 19
20
21
23 24
25 26
27 28
29 30
31 32
33 34
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 4 35 36 37 38
37 38
39 40
40 41 42
43
44 45
46 47
48 ⊿q

Variables	Number of items	Sample items	Response choices	Instructions
		From which source <i>would you most prefer</i> to receive information about the HPV vaccine?	have never heard about the HPV vaccine before today; ^d Public health brochures, pamphlets, flyers, or posters; Commercials or advertisements from pharmaceutical companies; Doctor, nurse, or other health care provider; Family member(s); Friend, peer, or co- worker; Information from my child or children's school; Newspapers or magazines; TV or the radio; The internet (e.g., health related websites, news); Social media (Facebook/Twitter).	apply to you.
HPV Vaccine Coverage	6	Did [CHILD] receive the HPV vaccine? ^c	Yes; No; I don't know	Please answer the following questions to th best of your ability
Health Care Provider Recommendation	4	Has [CHILD] seen a health care provider (e.g. a family doctor, paediatrician, or nurse) within the last 12 months? ^c Have you discussed [CHILD] receiving the HPV vaccine with a health care provider (e.g. a doctor, paediatrician, or nurse) within the last 12 months? ^c	Yes; No	
HPV Attitudes and Beliefs ⁷⁴	71 ^b	 Benefits (10): I feel that the HPV vaccine is effective in preventing HPV-related cancers. Accessibility (4): I feel that the process of actually getting the HPV vaccine for [CHILD] would be easy.^c Affordability (3): I feel that the HPV vaccine cost more than I can afford. Harms (8): I feel that the HPV vaccine is unsafe. Barriers Additional Items (4): I feel that I am concerned that the HPV vaccine might cause short term problems like pain or discomfort. Severity/Perceived Threat (3): I feel that it would be serious if [CHILD] contracted genital warts later in life.^c 	Strongly Disagree – Strongly Agree (7-point Likert scale)	Please select the answer that best reflects your attitude/belief.

Variables	Number of items	Sample items	Response choices	Instructions
		Susceptibility/Risk (3): I feel that without the HPV vaccine, [CHILD] would be at risk of getting genital warts later in life. ^c Social Norms/Influence (8): I feel that my friends are getting their children vaccinated with the HPV vaccine. Self-Efficacy (4): I feel that I am competent to make decisions about the vaccines [CHILD] receives. ^c Gender (3): I feel that HPV vaccine is important for girls. Trust (4): I feel that I trust the information I receive about vaccines. Communication (5): I feel that I am uncomfortable talking to [CHILD] about the HPV vaccine. ^c Risk Denial (1): HPV vaccination is not really necessary because Pap smears can be done to make sure cervical cancer doesn't develop. Additional Vaccine Items (7): I feel that child vaccinations should be mandatory.		
Motivation	8	Please rate the following reasons for why you would AGREE with your child receiving the HPV vaccine. Because I want [CHILD] to receive the HPV vaccine. ^c	Strongly Disagree – Strongly Agree (7-point Likert scale)	Please select the answer that best reflects your attitude/ belief. Please respond to the following statements to the best of your ability.
Vaccine Hesitancy ⁷⁷	10 ^b	Childhood vaccines are important for my child's health.	Strongly Disagree – Strongly Agree (5-point Likert scale)	How much do you agree with the each of the following statement on vaccinations?
Vaccine Refusal	3	Have you ever refused vaccinating [CHILD] with the human papillomavirus (HPV) vaccine? ^c Have you ever refused vaccinating [CHILD] with any childhood vaccine other than the human papillomavirus (HPV) vaccine? ^c	Yes; No	
Vaccine Conspiracy Beliefs Scale ⁷⁰	11 ^b	Vaccine safety data is often fabricated	Strongly Disagree – Strongly Agree (7-point Likert scale)	Please respond to the following statements to the best of your ability.

Variables	Number of items	Sample items	Response choices	Instructions
Open Ended Qualitative Items	5	What immediately comes to mind when thinking of childhood immunization? ⁷⁸	Free-text responses	
		What would influence your decision to have [CHILD] vaccinated or not against HPV? ^c		

Note. ⁴Survey is terminated if participant selects option "No"; ^bItems were administered in a random order; ⁶Participants were asked at the beginning of the questionnaire to provide a name, nickname, initials or abbreviations for their child who is between the ages of 9 and 16 and who has had the *most recent birthday*. Using intelligence programming, parents' child initials, name, nickname (e.g., Alex, PT, Jess) was then replaced for "[CHILD]" in all items, making the questionnaire individualized for each participant, ⁴If the respondent selected the option of 'Not applicable I have never heard about the HPV vaccine before today' then all other options will disappear.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Investigating Canadian parents' HPV vaccine knowledge, attitudes, and behaviour: A study protocol for a longitudinal national online survey

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-017814.R1
Article Type:	Protocol
Date Submitted by the Author:	27-Jul-2017
Complete List of Authors:	Shapiro, Gilla; McGill University, Department of Psychology ; Sir Mortimer B Davis Jewish General Hospital, Lady Davis Institute for Medical Research Perez, Samara; Sir Mortimer B Davis Jewish General Hospital, Lady Davis Institute for Medical Research Naz, Anila ; Sir Mortimer B Davis Jewish General Hospital, Lady Davis Institute for Medical Research Tatar, Ovidiu; Sir Mortimer B Davis Jewish General Hospital, Lady Davis Institute for Medical Research Guichon, Juliet; University of Calgary, Department of Community Health Sciences Amsel, Rhonda; McGill University, Department of Psychology Zimet, Gregory; Indiana University, Department of Psychology; Sir Mortimer B Davis Jewish General Hospital, Lady Davis Institute for Medical Research
Primary Subject Heading :	Infectious diseases
Secondary Subject Heading:	Health services research, Oncology, Paediatrics, Public health, Sexual health
Keywords:	Human papillomavirus, Canada, adolescent health, sexually transmitted infections, cancer prevention, vaccination

SCHOLARONE[™] Manuscripts

BMJ Open

Investigating Canadian parents' HPV vaccine knowledge, attitudes, and behaviour: A study protocol for a longitudinal national online survey

Gilla K. Shapiro^{1,2,*}, MA (*Cantab*), MPP/MPA, PhD(c); Samara Perez, PhD^{1,2}; Anila Naz², MD, MPH, MSc; Ovidiu Tatar², MD, MSc; Juliet R. Guichon³, BCL, MA (*Oxon*), SJD; Rhonda Amsel¹, MD, MSc, FCFP, DrPH; Gregory D. Zimet⁴, PhD, HSPP; Zeev Rosberger^{1,2,5,6}, PhD

***Corresponding author:** Gilla K. Shapiro, MA (*Cantab*), MPP/MPA, PhD(c), Department of Psychology, McGill University, 1205 Dr. Penfield Avenue, Montreal, Quebec, H3A 1B1; Tel: (514) 340-8222, Ext. 3978; E-mail: <u>gilla.shapiro@mail.mcgill.ca</u>

¹Department of Psychology, McGill University 1205 Dr. Penfield Avenue, Montreal, Quebec, H3A 1B1, Canada

²Lady Davis Institute for Medical Research, Jewish General Hospital 4333 Cote St-Catherine Road, Montreal, Quebec, H3T 1E4, Canada

³Department of Community Health Sciences, Faculty of Medicine, University of Calgary 3280 Hospital Drive, Calgary, Alberta, T2N 4N1, Canada

⁴Section of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, 410 West 10th Street, Suite 1001, Indianapolis, Indiana, 46202, USA

⁵Louise Granofsky Psychosocial Oncology Program, Segal Cancer Center, Jewish General Hospital, 4333 Cote St-Catherine Road, Montreal, Quebec, H3T 1E4, Canada

⁶Departments of Psychiatry and Oncology, McGill University 1205 Dr. Penfield Avenue, Montreal, Quebec, H3A 1B1, Canada

Word Count: 4,101

ABSTRACT

Introduction: Human papillomavirus (HPV), a sexually transmitted infection, can cause anogenital warts and a number of cancers. To prevent morbidity and mortality, three vaccines have been licensed and are recommended by Canada's National Advisory Committee on Immunization (for girls since 2007 and boys since 2012). Nevertheless, HPV vaccine coverage in Canada remains suboptimal in many regions. This study will be the first to concurrently examine the correlates of HPV vaccine decision-making in parents of school-aged girls and boys, and evaluate changes in parental knowledge, attitudes and behaviours over time.

Methods and analysis: Using a national, online survey utilizing theoretically driven constructs and validated measures, this study will identify HPV vaccine coverage rates and correlates of vaccine decision-making in Canada at two time points (August-September, 2016; and June-July, 2017). 4606 participants will be recruited to participate in an online survey through a market research and polling firm using email inventions. Data cleaning methods will identify inattentive or unmotivated participants.

Ethics and dissemination: The study received research ethics board approval from the Research Review Office, Integrated Health and Social Services University Network for West-Central Montreal (CODIM-FLP-16-219). The study will adopt a multi-modal approach to disseminate the study's findings to researchers, clinicians, cancer and immunization organizations, and the public in Canada and internationally.

KEYWORDS

Attitudes, behaviour, Canada, cancer prevention, decision-making, human papillomavirus, knowledge, sexually transmitted infections, parents, vaccination.

ARTICLE SUMMARY

Strengths and limitations of this study:

- Strengths of the study include a large sample size (n=4606), a nationally representative sample, use of psychometrically validated scales, the use of theoretical frameworks, a mixed methods approach, a wider range of constructs than in previous studies, and sophisticated data cleaning techniques to exclude inattentive or unmotivated responders.
- Limitations of this study include relying on self-reported data.

INTRODUCTION

Human papillomavirus (HPV) is the most common sexually transmitted infection.¹⁻⁴ While most HPV infections are asymptomatic and do not progress to disease,⁵⁻⁷ some infections can cause substantial morbidity and mortality.⁸⁻¹¹ It is estimated that 5.2% of all worldwide cancers are attributable to HPV.¹¹⁻¹³ HPV-associated cancers include cervical, oropharyngeal, anal, vaginal, vulvar, and penile.^{9 11} Combined, HPV is responsible for over 4,000 new cancer cases annually in Canada.⁹ Certain strains of HPV (e.g. HPV 6/11) also cause anogenital warts.¹⁴ HPV-associated disease can impact quality of life and accrue substantial costs to the health care system.^{9 10 15}

Three prophylactic vaccines that prevent against the oncogenic strains of HPV have been developed and recommended: the bivalent Cervarix[®], quadrivalent Gardasil[®], and nonavalent Gardasil[®]9.¹⁶ These vaccines are safe and effective.¹⁷⁻²³ Canada's National Advisory Committee on Immunization (NACI) has recommended the HPV vaccines for girls (since 2007) and boys (since 2012) ages 9 to 26.^{16 2} From 2007 to 2010, all Canadian provinces and territories implemented publicly funded, school-based vaccination programs for girls, albeit at different ages (i.e. 9 to 13 years of age) and with different dosing schedules (i.e. two or three doses).^{24 25} Vaccinating children at this age provides the highest level of immunogenicity and protects individuals before they are sexually active and thereby at risk of infection.^{9 20} This approach is similar to the majority of countries that provide publicly funded HPV vaccination programs to girls.²⁶

To date, only a handful of countries have extended their publicly funded, school-based HPV vaccination programs to boys.^{27 25 28} Canada has been an international leader in providing gender-neutral HPV vaccination;²⁵ by September 2017, 10 of Canada's 13 regions will have commenced school-based HPV vaccination programs that include boys (Figure 1).²⁹⁻³⁶ However, implementation of male HPV vaccination across Canada has been staggered, presenting a natural experiment to evaluate and compare the impact of the introduction of the HPV program on parents' attitudes, knowledge, and vaccine coverage.

Achieving high levels of vaccine coverage protects individuals and helps prevent transmission to unvaccinated partners, which maximizes population-level effectiveness (i.e. through herd protection).³⁷ HPV vaccination programs in Canada are not reaching their target

Page 5 of 27

BMJ Open

rates of immunization.^{38 39} HPV vaccine uptake rates in Canada vary considerably by region; in a national survey of parents of 12-14 year old girls, Gilbert et al. reported vaccination rates between 52.6% and 89.7% (2013 data).⁴⁰ On average, HPV vaccine uptake across Canada was 72.3%.⁴⁰ Preliminary evidence for boys in P.E.I.'s school-based vaccination program indicates 85.4% vaccine uptake (2013/2014 data).²⁹ However, a national survey of Canadian parents found uptake rates for boys in the context of (only one then two) publicly funded school-based programs, was extremely low (<3% nationwide; 2013 data).⁴¹ The lack of a national immunization registry makes it difficult to compare HPV vaccine coverage rates, and no national survey has yet examined HPV vaccine coverage in boys and girls simultaneously.

Given that parental consent is required for school-based immunisation programs for children in Canada, the NACI and Canadian Immunization Committee (CIC) have made it a research priority to understand why parents delay or refuse to vaccinate their children.^{9 24} Accordingly, this study seeks to understand the sociodemographic, psychosocial, and behavioural correlates of HPV vaccine coverage. Over the last decade, a number of studies have identified factors associated with HPV vaccination decision making including demographics, knowledge, attitudes, social norms, logistics (e.g. time, effort), and cost.⁴²⁻⁵³ The evidence has indicated some common themes (e.g. the importance of physician recommendation, perceived benefit, perceived safety, cost), and some contradictory evidence (e.g. knowledge has been found to correlate both negatively and positively with vaccine acceptance).^{48 49 54} The degree to which each of these factors contributes (i.e. the effect size) and possible policy variations between jurisdictions remains largely unclear. In addition, despite several systematic reviews, 48 49 51 53 55 not all potentially relevant factors (e.g. the effect of vaccine conspiracy beliefs) have been identified or comprehensively investigated in large population-based studies, especially in the Canadian context.⁵⁶ Furthermore, the majority of studies addressing parental HPV vaccine decision-making have been primarily focused on parents of girls,^{40 57} with fewer studies evaluating and making comparisons with parental HPV vaccine decision-making for boys.⁵⁸⁻⁶⁰

The present study aims to address these research gaps. Using a national, online survey utilizing theoretically driven constructs and validated questionnaires, this study identifies HPV vaccine coverage and correlates of decision-making in Canada. It will be the first to study concurrently the correlates of decision-making in Canadian parents of eligible school-aged boys and girls. This study will administer a survey at two time points (August-September, 2016; and

June-July, 2017) to capture important factors related to HPV vaccine hesitancy, acceptance and variation over time. Accordingly, this study will elucidate psychosocial factors that influence parents to vaccinate their sons or daughters contemporaneously and evaluate changes in parental knowledge, attitudes and behaviours over time.

Study Objectives and Hypotheses

The main objectives of this study are:

1. To describe HPV vaccine coverage in Canadian boys and girls

In the absence of a national immunization registry,⁶¹ current information on HPV vaccine coverage is unclear and continually evolving. We aim to determine HPV vaccine coverage in boys and girls nationally and across Canadian jurisdiction, and how rates change over time.

2. To assess the correlates of HPV vaccination in parents of boys and girls

In order to improve programs, it is important to understand the factors associated with HPV vaccine uptake. To date, Canadian studies have assessed the correlates of HPV vaccine uptake in parents of girls and parents of boys separately.^{52 58} Because the HPV vaccine is available to girls and boys of varying ages, we aim to understand the determinants of HPV vaccine uptake in these groups, using constructs from the Health Belief Model (HBM), a commonly used theoretical model that includes core beliefs that are hypothesized to predict the adoption of new health behaviours.⁶² The HBM has been used to examine various health-related behaviours, including cancer prevention and vaccination.^{63 64} As applied to HPV vaccination, elements of the HBM include perceived benefits of, and barriers to, HPV vaccination; perceived severity of, and susceptibility to, HPV infection and disease; and external influences prompting HPV vaccine uptake (i.e. cues to action). This study will use HBM constructs and other important predictors to evaluate, compare, and contrast. We hypothesize that higher HPV vaccine uptake will be significantly related to greater HPV knowledge, HBM constructs (particularly lower 'barriers' and more 'cues to action'), non-HBM attitudinal constructs (e.g.

Page 7 of 27

BMJ Open

lower vaccine conspiracy beliefs), and health care provider (HCP) recommendation. In parents of boys, a publicly funded program (that reduces barriers of cost and access) and HCP recommendation are hypothesized to be particularly important.

3. To identify Canadian parents' stage of decision-making by gender and province

Few studies have examined the stages of parents' vaccine decision. Assessing differences in parents' HPV vaccine decision-making stage is important for identifying how best to intervene for parents at different stages.^{58 65} Using the Precaution Adoption Process Model (PAPM), a stage-based theoretical model, we will classify parents according to their unique stage of HPV vaccine decision-making and examine the associated attitudes with that stage.⁶⁵⁻⁶⁷ The PAPM, as applied to HPV vaccination, identifies individuals along six stages of decision-making: 1) unaware of the vaccine; 2) unengaged in the decision to vaccinate their child; 3) undecided about whether to vaccinate their child; 4) *decided not to act* (i.e. decided not to vaccinate their child); 5) decided to act (i.e. decided to vaccinate their child); and 6) acted (i.e. vaccinated their child) (see Supplementary File). We will compare the stage of decision-making of parents of girls with boys, as well as the stages of parents in those regions that have publicly funded programs for boys (P.E.I., Alberta, Nova Scotia, Ontario, Quebec, Manitoba) with those that do not (i.e. British Columbia, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nunavut, Saskatchewan, Yukon). We hypothesize that parents of boys will be in earlier PAPM stages compared to parents of girls, and that parents of boys in regions without an HPV vaccine program will be in earlier stages compared to parents of boys in regions with a program.

4. To determine the impact of publicly funded HPV vaccine program initiation for boys

HPV vaccination programs for boys were implemented in Quebec, Ontario and Manitoba in the Fall of 2016, which is after Time 1 survey administration (August-September 2016), but before launching the Time 2 survey (June-July 2017). This natural experiment allows us to evaluate the impact of introducing a public school-based HPV vaccination program on parents' HPV vaccine knowledge, attitudes, and HPV vaccine coverage. Accordingly, we will assess whether these factors change from Time 1 to Time 2. We hypothesize that compared to programs

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

with no change to their public vaccination program, at Time 2 (post-intervention) parents of boys in Manitoba, Ontario and Quebec will have increased HPV vaccine knowledge, more positive HPV vaccine attitudes, be more likely to have received a HCP's recommendation, and be more likely to have received the HPV vaccine. British Columbia, Saskatchewan, New Brunswick, and Newfoundland and Labrador have announced that they would fund HPV vaccine for boys to begin in September 2017 (Figure 1); this research will therefore have value in predicting how parental attitudes regarding vaccinating their sons might change in those jurisdictions.

METHODS AND ANALYSIS

Study Design

This study uses a longitudinal design to collect self-reported data through an online questionnaire from a large national sample of Canadian parents. Surveys are administered at two time points: Time 1 during August-September (2016) and Time 2 during June-July (2017). Participants who responded to the survey at Time 1 were contacted again at Time 2 using the same questionnaire.

Sample

This study targets parents and guardians (hereafter referred to as "parents") of 9 to 16year-old boys and girls across Canada. This population is targeted because, on the younger side (i.e. age 9), it includes the youngest children included in NACI's recommendation and, on the older side (i.e. age 16), it includes children who, generally speaking, require parental consent in Canada.⁶⁸ Parents will be recruited by Canada's largest market research and polling firm, Leger-*The Research Intelligence Group*. Leger maintains a national panel of 400,000 Canadians who have Internet access, reside in Canada, and are fluent in English or French. This study targeted parents who have a child between 9-16 years of age living in their household. Participants completing the questionnaire at Time 1 will be contacted again at Time 2.

Leger's panels include individuals of all profiles with regard to gender, age, education

Page 9 of 27

BMJ Open

level, household composition and income for all regions, making it feasible to effectively target specific participants.⁶⁷ The panel is constructed to be nationally, as well as regionally, representative. Leger uses proprietary software informed by Canada's census data in order to generate a representative sample of the population. Leger's software follows an interactive algorithm to invite participants according to specified eligibility criteria. In this study, Leger's software enables extraction of all active and available panellists who meet the screening criteria, random sorting of the selected sample pool, examination of the number of panellists who satisfy each target group (i.e. parents of a 9-16 year old boys or parents of a 9-16 year old girls), and recalculation and balancing of the sample across the target groups. To recruit participants, Leger sends an email invitation and survey link to selected panellists. Leger sends a maximum of three reminder emails to its selected panellists to complete the survey until the required numbers of participants are recruited.

This study's sample size calculation takes into account previous research indicating that approximately 15% of respondents are inattentive or unmotivated responders who would be excluded using rigorous data cleaning methods.^{66 69} To evaluate different stages of decision making (objective 3), we are guided by previous research that found few individuals in particular stages (especially in less populated regions).⁶⁶ An attrition rate (of approximately 40-50%) from the first wave of data collection (Time 1, August-September 2016) to the second wave (Time 2, June-July 2017) is also expected.⁶⁶ Therefore, in order to attain a sufficient number of respondents to enable analyses of HPV vaccine decision-making by stage and region, this study recruits approximately 4,600 parents of school-aged children (ages 9-16) at Time 1, equally divided between parents of boys and parents of girls.

Measures

We use an online questionnaire that incorporates intelligent programming, such that the child's first name is included in the survey questions and parents receive questions that are personalized for them. Questionnaire items include previously validated scales.⁷⁰⁻⁷⁴ Participants will be asked to identify themselves as a parent or guardian, report the number of children they have, and their children's ages and genders. Parents with more than one child who meets the inclusion criteria will be asked to answer the questionnaire for the child who has had the most

recent birthday, a randomization technique previously employed.⁶⁶ The questionnaire assesses socio-demographics; HPV and HPV vaccine knowledge (using validated scales);⁷¹ PAPM stage; HPV vaccine willingness; HPV vaccine coverage; HCP recommendation (including the strength of the recommendation); HPV attitudes (using validated scales);^{73 75} motivation towards vaccination; vaccine hesitancy (using a developed scale);⁷⁴ and vaccine conspiracy beliefs (using a validated scale).⁷⁰ Items within validated questionnaires are administered in a random order to ameliorate any order effect and invariant responding.⁷⁶ Five open-ended qualitative questions will provide nuance in capturing details of parents' subjective perspectives on decision-making.⁷⁷ A detailed description of the questionnaire's items can be found in the Supplementary File.

To take into account language and literacy level, the questionnaire was adjusted to a grade eight reading level. To ensure the questionnaire could be answered in either of Canada's national languages, the English questionnaire was translated into French using Asiatis, an international translation service company. Bilingual team members verified the French translation and back-translation.

Data Collection and Management

Leger will facilitate data collection. Participants will be sent an email invitation to participate in a questionnaire and then assigned a unique access number. By accessing the questionnaire with this unique number, the respondent enters a secure account that ensures confidentiality. Moreover, if necessary, respondents may stop and resume the questionnaire where they left off so that they participate at a time that best suits them, allowing them to complete the questionnaire conscientiously.

Participants will be paid a modest cash amount in accordance with standard panel member compensation of Leger. Data collection at both time periods will be completed within four weeks. Missing data will not be an obstacle in this survey because participants will be required to answer all questions before moving from one page to the next. Once participants complete the questionnaire they will be debriefed, informed about HPV vaccination, and provided with informational resources. Leger will transfer the anonymized raw data file to our research team, which will be stored on a secure server at the Lady Davis Institute for Medical Research site of the Integrated Health and Social Services University Network for West-Central

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Montreal.

Data Cleaning Procedure

As recommended in the literature,^{69 76 78} data cleaning methods will be used to identify participants who might not have used appropriate care while completing the questionnaire (i.e. inattentive or unmotivated responders). Consistent with DeSimone et al. (2015) and Perez et al. (2016), we will use data cleaning methods that are direct (i.e. bogus items) and statistical (i.e. psychometric synonyms and psychometric antonyms).^{66 76}

Bogus items will be used to screen inattentive or unmotivated responders. Two bogus items on Likert scales were randomly inserted into the survey: "I have never met anyone younger than I am" and "I have been to every country in the world" (measured from '1-strongly disagree' to '7-strongly agree'). Incorrect answers (i.e. agreement) to both bogus items suggest inattentive or unmotivated responders. Incorrect responses are indicative of lack of attention. Respondents who answer at least one bogus item correctly will be retained.

Psychometric synonyms and antonyms data cleaning methods statistically examines response patterns.⁶⁶ Providing different responses to similar items suggests insufficient attention and accuracy in answering the questionnaire. Items measured on Likert scales will be selected and inter-item correlations will be calculated. Positively correlated pairs of items will constitute psychometric synonyms while negatively correlated pairs will constitute psychometric antonyms.⁷⁶ The number of pairs cannot be anticipated before beginning data analysis because it depends on the degree of correlation and the chosen cut-off value of the correlation coefficient.⁷⁶ We will use an inter-item Pearson correlation cut-off of 0.60 and -0.60 for selecting psychometric synonyms and psychometric antonyms pairs respectively, consistent with recommendations of Meade and Craig (2012).⁷⁸ Once the pairs have been identified, an index will be calculated for each respondent by correlating the responses to the first items of the pairs with the responses to the second items of the pairs.

Responders who meet both the bogus item and the psychometric synonyms/antonyms criteria will be considered attentive responders and retained.

Data Analysis Plan

In line with the first research objective to provide an accurate description of HPV vaccine coverage, we will report HPV vaccination coverage as percentage of girls and boys in each region and age group whose parents report they have received one, two, or three doses of the HPV vaccine. To test for statistically significant differences in proportions, we will use Pearson's Chi square tests and two sample tests of proportions.

For the second objective, to assess the correlates of HPV vaccine uptake in Canada, HPV vaccine uptake (dependent variable) will be dichotomised into "vaccinated" (i.e. received at least one dose of the HPV vaccine) and "non-vaccinated". Logistic regressions will be used to estimate the odds of vaccine uptake based on the correlates of interest, including socio-demographics, attitudes (informed by the HBM), knowledge, and behaviours (e.g. discussion with HCP). Significant associations between the correlates and vaccine uptake will be tested using bivariate logistic regression analyses. Multivariate logistic regression modelling will then be performed with all correlates from the bivariate analysis entered simultaneously. The model will be tested for goodness of fit, discrimination capacity, and multicollinearity.

To identify Canadian parents' stage of decision-making by gender and region (objective 3), we will report parents' HPV vaccine decision-making in percentages based on the six stages of the PAPM. For assessing significant differences in PAPM stage based on gender (at Time 1) and availability of publicly funded HPV vaccination programs for boys (at both Time 1 and Time 2), Pearson chi-square test and two sample tests of proportions will be used.

Lastly, to determine the impact of publicly funded HPV vaccine program initiation for boys in some regions, we will examine changes in parents' of boys (HPV and HPV vaccine) knowledge and attitudes (e.g. on the Human papillomavirus Attitudes and Beliefs Scale, Vaccine Conspiracy Beliefs Scale, and Vaccine Hesitancy Scale) before and after the introduction of the funded program. Parents of boys in provinces that introduced the program will be compared to parents of boys in regions with no change to their program. Significant differences from Time 1 to Time 2 will be tested using paired T-tests.

ETHICS AND DISSEMINATION

BMJ Open

Study Ethics

The study received research ethics board approval from the Research Review Office, Integrated Health and Social Services University Network for West-Central Montreal (CODIM-FLP-16-219). This is a university-affiliated teaching health care network where the coordinating centre (Lady Davis Institute for Medical Research) is based. Study participants consented to Leger's terms of use and privacy policy, which indicates that their data will be used anonymously for the research study.

Dissemination Plan

The study will adopt a multi-modal approach to disseminate the study's results to researchers, clinicians, cancer and vaccination organizations, and the public in Canada and internationally. Study findings will be published in peer-reviewed scientific journals (including open source). To assure wide availability of our results to the research community, journals will be selected that reach both research and health professional audiences.

Presentations will be made at national and international scientific meetings and symposia, such as the Canadian Immunization Conference, Canadian Association of Psychosocial Oncology, International Papillomavirus Society conference, and the International Psycho-Oncology Society. In addition, we will share the results with NACI, CIC, and provincial immunization advisory boards.

Given that the data is timely and could have immediate, direct implications for public education of Canadian parents, and more widespread influence on public health policy, we will prioritize analysis and dissemination of projects that have a potential for proximal public impact. We hope that sharing outcomes with non-profit organizations (e.g. the Canadian Cancer Society) will provide important platforms for innovative educational interventions based on this study's findings.

We will draft lay research summaries in media releases for dissemination to national media outlets and use such releases to help the public understand the importance of this research, bring the issues and challenges related to HPV vaccine acceptance to the public domain that will inform discussions about HPV vaccination.

DISCUSSION

Study Implications

By surveying a population-based representative sample of parents of eligible children, this study will provide current information about HPV vaccine coverage rates for both boys and girls nationally, and across Canadian jurisdictions (objective 1). Since HPV vaccine programs and policies are constantly evolving,²⁵ it is timely to evaluate comprehensively variations in program outcomes that target girls and boys, jurisdictions at a national and local level, and HPV vaccination by socio-demographic groups. For this reason, this study will be useful to policymakers in understanding where the HPV vaccination programs are meeting coverage targets, where disparities in vaccination exist, and which groups or jurisdictions may benefit from interventions designed to increase vaccination.

In order to improve the impact of publicly funded HPV vaccination programs, this study will examine the psychosocial and behavioural factors associated with parents' decisions to vaccinate their children and their decision-making stage (objectives 2 and 3). These theoretically driven investigations will enable policymakers to develop interventions to increase HPV vaccination that are evidence-based, tailored, and targeted towards parents' unique informational needs and their stage of decision-making, rather than providing all parents with the same messages.

Lastly, since Canada is one of the few countries that have implemented publicly-funded, national HPV vaccination programs, this research will make use of a natural experiment to evaluate the impact of the introduction of funded programs for boys on parents' vaccine knowledge, attitudes, and decision to vaccinate (objective 4). The results of this study will improve our understanding of the complex interplay of psychosocial and behavioural factors with policy decisions. By understanding this complexity, other countries can better anticipate that impact of policy changes.

The results generated by the study's four objectives will provide public health officials with critical information about HPV vaccination programs, improve the fields' understanding of

BMJ Open

influencers of decision-making, improve and enhance the delivery of current publicly funded HPV vaccination program, facilitate HPV vaccine uptake, and in turn decrease Canada's cancer burden and the associated human and economic cost.

Methodological Strengths

The recruitment strategy of using a marketing company (Leger) that maintains a nationally representative panel for data collection enables the sampling of a large number of parents who answer the survey within a short time frame. The precise recruitment period allows for data collection to occur in a timely manner and the provision of a snapshot of responses before and after the implementation of the HPV vaccination program for boys in certain provinces.

In addition, we use an online survey methodology with intelligent programming, which increases the quality of collected data by personalizing and tailoring the survey for each participant. This study also avoids the problems associated with missing data. To avoid the limitation of inattentive or unmotivated responding that is often found in survey data, this study will utilize sophisticated data cleaning techniques to remove such responders.

Further, the measures used in this study include psychometrically validated scales (where possible), which increase the reliability and validity of our results. Our survey also assesses diverse constructs. By using theoretical frameworks (such as the HBM and PAPM), we will be able to better understand the vaccine acceptability process, which is important in nuanced targeting of interventions. Lastly, by including quantitative and qualitative (open-ended) questions, we will be able to conduct additional mixed-methods studies to examine in-depth explanations of HPV vaccine decision making at different stage levels.

Foreseeable Limitations

One limitation of this study is the reliance on parents' self-reports of vaccination status for their children. In order to minimize this limitation, parents are asked about their vaccination status before and after reading an informative statement (whereby parents are provided details about the HPV vaccine). The exact number of reported doses (two or three) could also be

inaccurate. A possible way to confirm immunisation status is to request parents to check the immunisation record, contact the family doctor, or link to provincial immunization records. However, requesting participants to access records was not feasible in our study as such a request would have significantly increased the data collection time and costs. Another limitation of this study's design is that because we assess the same population at two time points, this study does not control for knowledge changes that occur as a result of the first survey. As our study's objective (objective four) is to compare provinces with and without provincial funding, this study makes the assumption that knowledge changes as a result of the first survey effects individuals from all provinces equally.

BMJ Open

Figure 1 Legend: This figure identifies the year that publicly funded school based HPV vaccine programs were initiated for girls and boys by Canadian jurisdiction.

Acknowledgements: The authors appreciate the guidance and expertise of Dr. Eve Dubé, Dr. Vladimir Gilca, Prof. Gina Ogilvie, and Prof. Eduardo Franco.

Contributors: GS conceived and designed the study, developed the survey, and wrote the manuscript. AN and OT participated in designing the study, assisted in drafting the manuscript, and provided critical feedback on manuscript revisions. SP, JG, GZ, RA provided critical feedback on manuscript revisions. All authors read and approved the final manuscript.

Funding: This work was supported by the Canadian Cancer Society Research Institute under the title: Understanding HPV Vaccine Hesitancy among Canadian Parents (Grant number: 704036). GS was supported by the Vanier Canada Graduate Scholarship and Queen Elizabeth II Diamond Jubilee Scholarship programs.

Competing Interests: ZR reports grants from the Canadian Cancer Society Research Institute during the conduct of the study, and personal fees from Merck outside the submitted work. GZ reports grants from Merck, and personal fees from Sanofi Pasteur, outside the submitted work. The remaining authors declare no conflict of interest.

Ethics approval: The study received research ethics board approval from the Research Review Office, Integrated Health and Social Services University Network for West-Central Montreal (CODIM-FLP-16-219).

Data sharing statement: Please contact the corresponding author if you are interested in using our survey or data.

REFERENCES

- 1. Shearer BD. HPV Vaccination: Understanding the Impact on HPV Disease. *Purple Paper* 2011; 34. <u>http://www.nccid.ca/files/Purple_Paper_Note_mauve/PP_34_EN.pdf</u>.
- 2. National Advisory Committee on Immunization. Update on the recommended Human Papillomavirus vaccine immunization schedule 2015 [Available from: <u>http://publications.gc.ca/collections/collection_2015/aspc-phac/HP40-128-2014-eng.pdf</u> accessed May 08 2017.
- 3. Crosbie EJ, Einstein MH, Franceschi S, et al. Human papillomavirus and cervical cancer. *Lancet* 2013;382(9895):889-99. doi: 10.1016/S0140-6736(13)60022-7
- 4. Moore RA, Ogilvie G, Fornika D, et al. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination. *Cancer Causes Control* 2009;20(8):1387-96. doi: 10.1007/s10552-009-9365-4
- 5. Little KQ, Ogilvie G, Mirwaldt P. Human papillomavirus awareness, knowledge, and vaccination status in a diverse population of male postsecondary students in Greater Vancouver. *British Columbia Medical Journal* 2015;57(2)
- 6. Parkin DM, Bray F. The burden of HPV-related cancers. *Vaccine* 2006;24:S11-S25.
- 7. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. *Gynecol Oncol* 2007;107(2 Suppl 1):S2-5. doi: 10.1016/j.ygyno.2007.07.067
- 8. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens Part B: biological agents. *The Lancet Oncol* 2009;10(4):321-22.
- 9. National Advisory Committee on Immunization. Update On Human Papillomavirus Vaccines. *Canada Communicable Disease Report* 2012;38
- 10. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. *Vaccine* 2012;30 Suppl 5:F12-23. doi: 10.1016/j.vaccine.2012.07.055
- 11. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *Lancet Oncol* 2012;13(6):607-15. doi: 10.1016/S1470-2045(12)70137-7
- 12. Parkin DM. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer* 2006;118(12):3030-44. doi: 10.1002/ijc.21731
- 13. Oh JK, Weiderpass E. Infection and cancer: global distribution and burden of diseases. *Ann Glob Health* 2014;80(5):384-92. doi: 10.1016/j.aogh.2014.09.013
- 14. Ball SL, Winder DM, Vaughan K, et al. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. *J Med Virol* 2011;83(8):1345-50. doi: 10.1002/jmv.22111
- 15. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. *Sex Transm Infect* 2009;85(2):111-5. doi: 10.1136/sti.2008.030999
- 16. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Updated Recommendations on Human Papillomavirus (HPV) vaccines: 9-valent HPV vaccine and clarification of minimmum intervals between doses in the HPV immunization schedules Ontario, Canada2016 [Available from: <u>http://www.healthycanadians.gc.ca/publications/healthy-living-vie-saine/human-papillomavirus-9-valent-vaccine-update-recommendation-mises-a-jour-</u>

1 2	
3 4	
5 6	
7 8 9	
9 10 11	
12 13	
14 15	
16 17 18	
19 20	
21 22	
23 24	
25 26 27	
$\begin{array}{c} 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 4\end{array}$	
30 31	
32 33	
34 35 36	
37 38	
39 40	
41 42 43	
43 44 45	
46 47	
48 49	
50 51 52	
52 53 54	
55 56	
57 58	
59	

<u>recommandations-papillome-humain-vaccin-nonavalent/alt/hpv-phv-eng.pdf</u> accessed February 14 2017.

- 17. Szarewski A, Poppe WA, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. *Int J Cancer* 2012;131(1):106-16. doi: 10.1002/ijc.26362
- 18. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. *Cancer Prev Res (Phila)* 2009;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031
- 19. Group FIIS, Dillner J, Kjaer SK, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. *BMJ* 2010;341:c3493. doi: 10.1136/bmj.c3493
- 20. Ferris D, Samakoses R, Block SL, et al. Long-term study of a quadrivalent human papillomavirus vaccine. *Pediatrics* 2014;134(3):e657-65. doi: 10.1542/peds.2013-4144
- 21. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *J Natl Cancer Inst* 2010;102(5):325-39. doi: 10.1093/jnci/djp534
- 22. Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. *Expert Opin Drug Saf* 2015;14(5):697-712. doi: 10.1517/14740338.2015.1013532
- 23. Ogilvie GS, Naus M, Money DM, et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. *Int J Cancer* 2015;137(8):1931-7. doi: 10.1002/ijc.29508
- 24. Canadian Immunization Committee. Recommendations for human papillomavirus immunization programs. *Canada Communicable Disease Report* 2014;40(8)
- 25. Shapiro GK, Guichon J, Prue G, et al. A Multiple Streams analysis of the decisions to fund gender-neutral HPV vaccination in Canada. *Prev Med* 2017;100:123-31. doi: 10.1016/j.ypmed.2017.04.016
- 26. Bonanni P, Bechini A, Donato R, et al. Human papilloma virus vaccination: impact and recommendations across the world. *Ther Adv Vaccines* 2015;3(1):3-12. doi: 10.1177/2051013614557476
- 27. Marsh K, Chapman R, Baggaley RF, et al. Mind the gaps: what's missing from current economic evaluations of universal HPV vaccination? *Vaccine* 2014;32(30):3732-9. doi: 10.1016/j.vaccine.2014.05.007
- 28. Patel C, Macartney K. Supporting the call for a gender-neutral human papillomavirus vaccination in Canada. *Cmaj* 2017;189(3):E118. doi: 10.1503/cmaj.732446
- 29. McClure CA, MacSwain MA, Morrison H, et al. Human papillomavirus vaccine uptake in boys and girls in a school-based vaccine delivery program in Prince Edward Island, Canada. *Vaccine* 2015;33(15):1786-90. doi: 10.1016/j.vaccine.2015.02.047
- 30. Public Health Agency of Canada. Canada's Provincial and Territorial Routine (and Catch-up) Vaccination Programs for Infants and Children. 2017 [Available from: <u>http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php</u> accessed May 08 2017.

- 31. Colbert Y. HPV vaccine for Nova Scotia boys called 'groundbreaking': CBC News; 2015 [Available from: <u>http://www.cbc.ca/news/canada/nova-scotia/hpv-vaccine-for-nova-scotia-boys-called-groundbreaking-1.3031169</u> accessed May 07 2017.
 - 32. Shapiro GK, Perez S, Rosberger Z. Including males in Canadian human papillomavirus vaccination programs: a policy analysis. *Cmaj* 2016;188(12):881-6. doi: 10.1503/cmaj.150451
 - 33. Ghoussoub M. B.C. extends free HPV vaccinations to Grade 6 boys British Columbia2017 [updated Jan 06, 2017. Available from: http://www.cbc.ca/news/canada/british-columbia/b-c-extends-free-hpv-vaccinations-to-grade-6-boys-1.3925212.
 - 34. Cover JK, Nghi NQ, LaMontagne DS, et al. Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. *BMC Public Health* 2012;12:629. doi: 10.1186/1471-2458-12-629
 - 35. Fong K. Grade 6 boys to start receiving HPV vaccination in Saskatchewan 2017 [updated March 23, 2017. Available from: <u>http://globalnews.ca/news/3331430/grade-6-boys-to-start-receiving-hpv-vaccinations-in-sask/</u> accessed May 08 2017.
 - 36. Boone M. Boys too: HPV vaccination to be offered to all N.L. students in Grade 6 2017 [updated May 04, 2017. Available from: <u>http://www.cbc.ca/news/canada/newfoundland-labrador/hpv-vaccine-boys-newfoundland-1.4098941</u> accessed May 08 2017.
 - 37. Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. *Lancet Infect Dis* 2015;15(5):565-80. doi: 10.1016/S1473-3099(14)71073-4
 - 38. Ministère de la Santé et des Services Sociaux. Programme National de Santé Publique. 2008. <u>http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2008/08-216-01.pdf</u>.
 - 39. Bogaards JA, Wallinga J, Brakenhoff RH, et al. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. *BMJ* 2015;350:h2016. doi: 10.1136/bmj.h2016
 - 40. Gilbert NL, Gilmour H, Dube E, et al. Estimates and determinants of HPV non-vaccination and vaccine refusal in girls 12 to 14 y of age in Canada: Results from the Childhood National Immunization Coverage Survey, 2013. *Hum Vaccin Immunother* 2016;12(6):1484-90. doi: 10.1080/21645515.2016.1153207
 - 41. Perez S, Shapiro GK, Brown CA, et al. 'I didn't even know boys could get the vaccine': Parents' reasons for human papillomavirus (HPV) vaccination decision making for their sons. *Psychooncology* 2015;24(10):1316-23. doi: 10.1002/pon.3894
 - 42. Ogilvie GS, Remple VP, Marra F, et al. Parental intention to have daughters receive the human papillomavirus vaccine. *Cmaj* 2007;177(12):1506-12. doi: 10.1503/cmaj.071022
 - 43. Allen JD, Coronado GD, Williams RS, et al. A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability. *Vaccine* 2010;28(24):4027-37. doi: 10.1016/j.vaccine.2010.03.063
 - 44. Krawczyk AL, Perez S, Lau E, et al. Human papillomavirus vaccination intentions and uptake in college women. *Health Psychol* 2012;31(5):685-93. doi: 10.1037/a0027012
 - 45. Ogilvie GS, Remple VP, Marra F, et al. Intention of parents to have male children vaccinated with the human papillomavirus vaccine. *Sex Transm Infect* 2008;84(4):318-23. doi: 10.1136/sti.2007.029389

1 2		
2	46.	Los A. Ho. M. Chaung CK at al. Easters influencing adolescent girls' decision in
4	40.	Lee A, Ho M, Cheung CK, et al. Factors influencing adolescent girls' decision in initiation for human papillomavirus vaccination: a cross-sectional study in Hong Kong.
5		
6	47	<i>BMC Public Health</i> 2014;14:925. doi: 10.1186/1471-2458-14-925
7 8	47.	Zimet GD, Rosberger Z, Fisher WA, et al. Beliefs, behaviors and HPV vaccine:
8 9		correcting the myths and the misinformation. Prev Med 2013;57(5):414-8. doi:
9 10		10.1016/j.ypmed.2013.05.013
11	48.	Hendry M, Lewis R, Clements A, et al. "HPV? Never heard of it!": a systematic review
12		of girls' and parents' information needs, views and preferences about human
13		papillomavirus vaccination. Vaccine 2013;31(45):5152-67. doi:
14		10.1016/j.vaccine.2013.08.091
15	49.	Holman DM, Benard V, Roland KB, et al. Barriers to human papillomavirus vaccination
16		among US adolescents: a systematic review of the literature. JAMA Pediatr
17		2014;168(1):76-82. doi: 10.1001/jamapediatrics.2013.2752
18	50.	Patel PR, Berenson AB. Sources of HPV vaccine hesitancy in parents. <i>Hum Vaccin</i>
19 20	50.	Immunother 2013;9(12):2649-53. doi: 10.4161/hv.26224
20 21	51	
22	51.	Walhart T. Parents, adolescents, children and the human papillomavirus vaccine: a
23	50	review. Int Nurs Rev 2012;59(3):305-11. doi: 10.1111/j.1466-7657.2012.00991.x
24	52.	Krawczyk A, Knauper B, Gilca V, et al. Parents' decision-making about the human
25		papillomavirus vaccine for their daughters: I. Quantitative results. Hum Vaccin
26		Immunother 2015;11(2):322-9. doi: 10.1080/21645515.2014.1004030
27	53.	Trim K, Nagji N, Elit L, et al. Parental Knowledge, Attitudes, and Behaviours towards
28		Human Papillomavirus Vaccination for Their Children: A Systematic Review from 2001
29 30		to 2011. Obstet Gynecol Int 2012;2012:921236. doi: 10.1155/2012/921236
30 31	54.	Gowda C, Dempsey AF. The rise (and fall?) of parental vaccine hesitancy. Hum Vaccin
32		Immunother 2013;9(8):1755-62. doi: 10.4161/hv.25085
33	55.	Garcini LM, Galvan T, Barnack-Tavlaris JL. The study of human papillomavirus (HPV)
34		vaccine uptake from a parental perspective: a systematic review of observational studies
35		in the United States. <i>Vaccine</i> 2012;30(31):4588-95. doi: 10.1016/j.vaccine.2012.04.096
36	56.	Larson HJ, Jarrett C, Eckersberger E, et al. Understanding vaccine hesitancy around
37	50.	vaccines and vaccination from a global perspective: a systematic review of published
38		
39 40	57	literature, 2007-2012. Vaccine 2014;32(19):2150-9. doi: 10.1016/j.vaccine.2014.01.081
40 41	57.	Forster AS, Rockliffe L, Chorley AJ, et al. A qualitative systematic review of factors
42		influencing parents' vaccination decision-making in the United Kingdom. SSM Popul
43	- 0	Health 2016;2:603-12. doi: 10.1016/j.ssmph.2016.07.005
44	58.	Perez S, Tatar O, Gilca V, et al. Untangling the psychosocial predictors of HPV
45		vaccination decision-making stages among parents of boys. Vaccine 2017;Forthcoming
46	59.	Lindley MC, Jeyarajah J, Yankey D, et al. Comparing human papillomavirus vaccine
47		knowledge and intentions among parents of boys and girls. Hum Vaccin Immunother
48		2016;12(6):1519-27. doi: 10.1080/21645515.2016.1157673
49 50	60.	Radisic G, Chapman J, Flight I, et al. Factors associated with parents' attitudes to the
50 51		HPV vaccination of their adolescent sons : A systematic review. Prev Med 2017;95:26-
52		37. doi: 10.1016/j.ypmed.2016.11.019
53	61.	Government of Canada. Immunization coverage and registries 2016 [Available from:
54	01.	https://www.canada.ca/en/public-health/services/immunization-coverage-
55		registries.html#a3 accessed February 07 2017.
56		$\frac{1021501105.11011177a5}{1001001000000000000000000000000000000$
57		
58 50		
59 60		

- 62. Champion VL, Skinner CS. The Health Belief Model. In: Glanz K, Rimer BK, Viswanath KE, eds. Health behavior and health education: theory, research, and practice. 4th ed: John Wiley & Sons 2008:45-65.
 - 63. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. *Prev Med* 2007;45(2-3):107-14. doi: 10.1016/j.ypmed.2007.05.013
 - 64. Cunningham MS, Davison C, Aronson KJ. HPV vaccine acceptability in Africa: a systematic review. *Prev Med* 2014;69:274-9. doi: 10.1016/j.ypmed.2014.08.035
 - 65. Prue G, Santin O. HPV vaccine acceptance in male adolescents. *Psychooncology* 2015;24(10):1327-29. doi: 10.1002/pon.3961
 - 66. Perez S, Tatar O, Shapiro GK, et al. Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study. *BMC Public Health* 2016;16(1):1223. doi: 10.1186/s12889-016-3828-9
- 67. Weinstein ND. The precaution adoption process. *Health Psychol* 1988;7(4):355-86.
- 68. Court of Appeal of Alberta. J.S.C. v. Wren, 1986 ABCA 249 (CanLII) 31-12-1986 [March 21, 2017]. Available from: http://www.canlii.org/en/ab/abca/doc/1986/1986abca249/1986abca249.html.
- 69. Osborne JW. Best practices in data cleaning: A complete guide to everything you need to do before and after collecting your data: Sage Publications 2012.
- 70. Shapiro GK, Holding A, Perez S, et al. Validation of the vaccine conspiracy beliefs scale. *Papillomavirus Research* 2016;2:167-72. doi: 10.1016/j.pvr.2016.09.001
- 71. Perez S, Tatar O, Ostini R, et al. Extending and validating a human papillomavirus (HPV) knowledge measure in a national sample of Canadian parents of boys. *Prev Med* 2016;91:43-49. doi: 10.1016/j.ypmed.2016.07.017
- 72. Waller J, Ostini R, Marlow LA, et al. Validation of a measure of knowledge about human papillomavirus (HPV) using item response theory and classical test theory. *Prev Med* 2013;56(1):35-40.
- 73. McRee AL, Brewer NT, Reiter PL, et al. The Carolina HPV immunization attitudes and beliefs scale (CHIAS): scale development and associations with intentions to vaccinate. *Sex Transm Dis* 2010;37(4):234-9. doi: 10.1097/OLQ.0b013e3181c37e15
- 74. Larson HJ, Jarrett C, Schulz WS, et al. Measuring vaccine hesitancy: The development of a survey tool. *Vaccine* 2015;33(34):4165-75. doi: 10.1016/j.vaccine.2015.04.037
- 75. Perez S, Shapiro GK, Tatar O, et al. Development and Validation of the Human Papillomavirus Attitudes and Beliefs Scale in a National Canadian Sample. *Sex Transm Dis* 2016;43(10):626-32. doi: 10.1097/OLQ.000000000000506
- 76. DeSimone JA, Harms PD, DeSimone AJ. Best practice recommendations for data screening. *Journal of Organizational Behavior* 2015;36(2):171-81.
- 77. LaClair BJ, Smith S, Woodward J. Attitudes and concerns of Kansas parents related to childhood immunization. *Immunize Kansas Kids* 2014
- 78. Meade AW, Craig SB. Identifying careless responses in survey data. *Psychol Methods* 2012;17(3):437-55. doi: 10.1037/a0028085



Figure 1. Publicly funded school based HPV vaccine programs in Canada

91x68mm (300 x 300 DPI)

Supplementary	File:	Study	Questionnaire
---------------	-------	-------	---------------

Variables	Number of items	Sample items	Response choices	Instructions
Eligibility	5	Do you personally have a child between 9-16 years of age living in your household? ^a	Yes; No	
Socio-Demographics	18	In which province do you currently live? Which of the following ethnicities best describes you?	Categories derived from those commonly used by Statistics Canada. Prefer not to answer was an option for some items.	Select only one.
Precaution Adoption Process Model	1	Which of the following best described your thoughts about the human papillomavirus (HPV) vaccine for [CHILD]? ^c	Stage 1 : I am <i>unaware</i> that the HPV vaccine could be given to [CHILD name]; Stage 2 : I am aware that the HPV vaccine could be given to [CHILD name], but I have <i>never</i> <i>thought about</i> vaccinating [CHILD name] against HPV; Stage 3 : I am <i>undecided</i> about vaccinating [CHILD name] against HPV; Stage 4 : I have decided I DO <i>NOT</i> want to vaccinate [CHILD name] against HPV; Stage 5 : I have decided I <i>DO</i> want to vaccinate [CHILD name] against HPV; Stage 6 : [CHILD name] has <i>already received</i> the HPV vaccine. ^c	Select only one.
HPV & HPV Vaccine Perceived Knowledge	2	Before today, how much would you say you knew about the human papillomavirus (HPV)?	Nothing – A lot (5-point Likert scale)	Please answer the following questions to the best of your ability.
HPV Knowledge ¹²	23 ^b	HPV always has visible signs or symptoms (F) HPV can be passed on during sexual intercourse (T)	True; False; Don't know	Please answer the following questions about human papillomavirus (HPV) to the best of your ability.
HPV Vaccine Knowledge ¹²	13 ^b	The HPV vaccine offers protection against most cervical cancers (T) Girls who have had the HPV vaccine do not need a Pap test when they are older (F)	True; False; Don't know	Please answer the following questions abou the human papillomaviru (HPV) vaccine to the bes of your ability.

Variables	Number of items	Sample items	Response choices	Instructions
Information Sources	of items 2	Where have you heard about the HPV vaccine? From which source <i>would you most prefer</i> to receive information about the HPV vaccine?	Categories include: Not applicable, I have never heard about the HPV vaccine before today; ^d Public health brochures, pamphlets, flyers, or posters; Commercials or advertisements from pharmaceutical companies; Doctor, nurse, or other health care provider; Family member(s); Friend, peer, or co- worker; Information from my child or children's school; Newspapers or magazines; TV or the radio; The internet (e.g., health related websites, news); Social media	Check all answers that apply to you.
			(Facebook/Twitter).	
HPV Vaccine Coverage	6	Did [CHILD] receive the HPV vaccine? ^c	Yes; No; I don't know	Please answer the following questions to best of your ability
Health Care Provider Recommendation	4	Has [CHILD] seen a health care provider (e.g. a family doctor, paediatrician, or nurse) within the last 12 months? ^c Have you discussed [CHILD] receiving the HPV vaccine with a health care provider (e.g. a doctor,	Yes; No	
HPV Attitudes and Beliefs ³	71 ^b	 paediatrician, or nurse) within the last 12 months?^c Benefits (10): I feel that the HPV vaccine is effective in preventing HPV-related cancers. Accessibility (4): I feel that the process of actually getting the HPV vaccine for [CHILD] would be easy.^c Affordability (3): I feel that the HPV vaccine cost more than I can afford. Harms (8): I feel that the HPV vaccine is unsafe. Barriers Additional Items (4): I feel that I am concerned that the HPV vaccine might cause short term problems like pain or discomfort. Severity/Perceived Threat (3): I feel that it would be serious if [CHILD] contracted genital warts later 	Strongly Disagree – Strongly Agree (7-point Likert scale)	Please select the answer that best reflects your attitude/belief.

Variables	Number of items	Sample items	Response choices	Instructions
Motivation	of items	 in life.^c Susceptibility/Risk (3): I feel that without the HPV vaccine, [CHILD] would be at risk of getting genital warts later in life.^c Social Norms/Influence (8): I feel that my friends are getting their children vaccinated with the HPV vaccine. Self-Efficacy (4): I feel that I am competent to make decisions about the vaccines [CHILD] receives.^c Gender (3): I feel that HPV vaccine is important for girls. Trust (4): I feel that I trust the information I receive about vaccines. Communication (5): I feel that I am uncomfortable talking to [CHILD] about the HPV vaccine.^c Risk Denial (1): HPV vaccination is not really necessary because Pap smears can be done to make sure cervical cancer doesn't develop. Additional Vaccine Items (7): I feel that child vaccinations should be mandatory. 	Strongly Disagree – Strongly Agree (7-point Likert scale)	Please select the answer that best reflects your
		Because I want [CHILD] to receive the HPV vaccine. ^c		attitude/ belief. Please respond to the following statements to the best of your ability.
Vaccine Hesitancy ⁴	10 ^b	Childhood vaccines are important for my child's health.	Strongly Disagree – Strongly Agree (5-point Likert scale)	How much do you agree with the each of the following statement on vaccinations?
Vaccine Refusal	3	Have you ever refused vaccinating [CHILD] with the human papillomavirus (HPV) vaccine? ^c Have you ever refused vaccinating [CHILD] with any childhood vaccine other than the human papillomavirus (HPV) vaccine? ^c	Yes; No	

Variables	Number of items	Sample items	Response choices	Instructions
Vaccine Conspiracy Beliefs Scale ⁵	11 ^b	Vaccine safety data is often fabricated	Strongly Disagree – Strongly Agree (7-point Likert scale)	Please respond to the following statements to the best of your ability.
Open Ended Qualitative Items	5	What immediately comes to mind when thinking of childhood immunization? ⁶ What would influence your decision to have [CHILD] vaccinated or not against HPV? ^c	Free-text responses	

Note. ^a Survey is terminated if participant selects option "No"; ^b Items were administered in a random order; ^c Participants were asked at the beginning of the questionnaire to provide a name, nickname, initials or abbreviations for their child who is between the ages of 9 and 16 and who has had the *most recent birthday*. Using intelligence programming, parents' child initials, name, nickname (e.g., Alex, PT, Jess) was then replaced for "[CHILD]" in all items, making the questionnaire individualized for each participant; ^d If the respondent selected the option of 'Not applicable I have never heard about the HPV vaccine before today' then all other options will disappear.

References

- 1. Waller J, Ostini R, Marlow LA, et al. Validation of a measure of knowledge about human papillomavirus (HPV) using item response theory and classical test theory. *Prev Med* 2013;56(1):35-40.
- 2. Perez S, Tatar O, Ostini R, et al. Extending and validating a human papillomavirus (HPV) knowledge measure in a national sample of Canadian parents of boys. *Prev Med* 2016;91:43-49. doi: 10.1016/j.ypmed.2016.07.017
- 3. Perez S, Shapiro GK, Tatar O, et al. Development and Validation of the Human Papillomavirus Attitudes and Beliefs Scale in a National Canadian Sample. *Sex Transm Dis* 2016;43(10):626-32. doi: 10.1097/OLQ.000000000000506
- 4. Larson HJ, Jarrett C, Schulz WS, et al. Measuring vaccine hesitancy: The development of a survey tool. *Vaccine* 2015;33(34):4165-75. doi: 10.1016/j.vaccine.2015.04.037
- 5. Shapiro GK, Holding A, Perez S, et al. Validation of the vaccine conspiracy beliefs scale. *Papillomavirus Research* 2016;2:167-72. doi: 10.1016/j.pvr.2016.09.001
- 6. LaClair BJ, Smith S, Woodward J. Attitudes and concerns of Kansas parents related to childhood immunization. *Immunize Kansas Kids* 2014